 
STUDY PROTOCOL  
 
 
 
 
BRIDGING TRIAL TO EV ALUATE THE INFECTIVI TY EQUIVALENCE 
OF CURRENT AND NEW L OTS OF PLASMODIUM FA LCIPARUM 
STRAIN  NF54 (CLONE  3D7) WITHIN THE WRAIR CO NTROLLED 
HUMAN MALARIA INFECT ION (CHMI) MODEL  
 
 
 
NCT# 03882528  
 
Document Date:  13FEB2019  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 1 US Gove rnment Proprietary 1. TITLE PAGE 
BRIDGING TRIAL TO EVALUATE THE INFECTIVITY EQUIVALENCE 
OF CURRENT AND NEW LOTS OF PLASMODIUM FALCIPARUM 
STRAIN NF54 (CLONE 3D7) WITHIN THE WRAIR CONTROLLED 
HUMAN MALARIA INFECTION (CHMI) MODEL 
 
Sponsor  The Surgeon General, Department of the Army  
Sponsor’s Representative  
(Acting):  Mark S. Paxton, JD, MS  
US Army Medical Research and Materiel Command (USAMRMC)  
1430 Veterans Drive, Ft. Detrick, MD 21702 -5009  
301-619-0317; DSN: 343 -0317  
Fax: 301 -619-0197  
Email:  Mark.s.paxton.civ@mail.mil   
Source of Funding:  MIDRP  
Sponsor's Medical Expert 
for the Trial : James E. Moon, COL, MC, USA  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9176  
Fax: (301) 319 -9449  
Email: James.e.moon.mil@mail.mil  
Research  Monitor : 
 
 
  Ramiro Gutierrez, MD CAPT, MC, USN  
NMRC  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: 301-319-3193  
Email: Ramiro.l.gutierrez.mil@mail.mil  
Principal Investigator : James E. Moon, COL, MC, USA  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9176  
Fax: (301) 319 -7358  
Email: James.e.moon.mil@mail.mil  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 2 US Gove rnment Proprietary Subinvestigator s: Paige Waterman, MD  
COL, MC, USA  
WRAIR (Main Campus)  
Phone: 301 -319-9312  
Email: Paige.e.waterman.mil@mail.mil  
 Melinda Hamer, MD  
LTC, MC, USA  
WRAIR (Main Campus)  
Phone: 301 -319-3136  
Email: Melinda.j.hamer.mil@mail.mil  
 Christine Lee, MD  
WRAIR (Main Campus)  
Phone: 301 -319-9850  
Email: Christine.e.lee12.ctr@mail.mil  
 Michael Koren, MD  
MAJ, MC, USA  
WRAIR (Main Campus)  
Phone: (301) 319 -9904/(240) 274 -0158  
Email: Michael.a.koren2.mil@mail.mil  
 Julie Ake, MD  
LTC, MC, USA  
WRAIR Military HIV Research Program  
6720 -A Rockledge Drive  
Bethesda, MD 20817  
Phone: (301) 500 -3621  
Email: Jake@hivresearch.org  
 
 Justin Curley, MD  
LTC, MC, USA  
WRAIR (Main Campus)  
Phone: 301 -319-9687  
Email: Justin.m.curley.mil@mail.mil  
 Jesse DeLuca, DO  
LTC, MC, USA  
WRAIR (Main Campus)  
Phone: 301 -319-9418  
Email: Jesse.p.deluca.mil@mail.mil  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 3 US Gove rnment Proprietary  Ilin Chuang, MD  
CAPT, MC, USN  
Naval Medical Research Center  
Phone: (301) 319 -9786  
Email: I lin.chuang.mil@mail.mil   
 Judith Epstein, MD  
CAPT, MC, USN  
Naval Medical Research Center  
Phone: (301) 319 -7686  
Email: Judith.e.epstein.mil@mail.mil   
 Daniel Selig, MD  
CPT, MC, USA  
Phone: 240 -475-6111  
Email: daniel.j.selig.mil@mail.mil  
 Viseth Ngauy, COL, MC, USA  
Director, Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9389  
Fax: (301) 319 -7358  
Email : Viseth.ngauy.mil@mail.mil  
 Jack N. Hutter  MAJ, MC, USA  
Clinical Trials Center  
Walter Reed Army Institute of Research  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Telephone: 301 -319-3095  
Email: Jack.n.hutter.mil@mail.mil  
Research Associates:  Edwin Kama u, LTC , MS, USA  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
 Lindsey Garver, PhD  
Entomology Branch  
Walter Reed Army Institute of Research  
 Jack Komisar, PhD  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
Martha Sedegah, PhD 
Naval Medical Research Center  
 Elizabeth Duncan, MS  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 4 US Gove rnment Proprietary  Jangwoo Lee, CPT, MS, USA  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research  
 Sheila Peel, MSPH, PhD, DAC   
Department of Laboratory Diagnostics and Monitoring Military  HIV 
Research Program  
Walter Reed Army Institute of Research  
 Linda Jagodzinski, PhD  
Department of Laboratory Diagnostics and Monitoring  
Military HIV Research Program  
Walter Reed Army Institute of Research  
Clinical Trial Site  Clinical Trials Center , Room 2w78  
Center for Enabling Capabilities  
Walter Reed Army Institute of Research  
503 Robert Grant Ave.  
Silver Spring, MD 20910  
Te1: (301) 319 -9660  
Clinical Laboratories and Other Departments/Institutions Involved in the Trial  
Site Investigational 
Product Accountability  Lindsey Garver, PhD  
Entomology Branch  
503 Robert Grant Ave  
Silver Spring, MD 20910  
Tel: (301) -319-9824  
Fax: (301) 319 -9290  
Email:  Lindsey.s.garverbaldwin.civ@mail.mil  
Clinical Laboratory : Quest Diagnostics Inc.  
1901 Sulphur Spring Road  
Baltimore, MD 21227  
Tel: (410) 247 -9100  
Research Laborator ies:  Malaria Serology Laboratory, Malaria Vaccine Branch, Walter Reed Army 
Institute of Research  
Department of Molecular Parasitology, Malaria Vacci ne Branch, Walter 
Reed Army Institute of Research  
Department of Laboratory Diagnostics and Monitoring , Military HIV 
Research Program, Walter Reed Army Institute of Research  
Ombudsman:  Michael Hrycyk  
Quality Assurance Office  
Walter Reed Army Institute of Research  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 5 US Gove rnment Proprietary Statistician  Devin J. Hunt, MS  
Clinical Trials Center  
Walter Reed Army Institute of Research  
Silver Spring, MD 20910  
301-319-9571 (direct)  
301-452-0813 (mobile)  
Email: Devin.j.hunt.ctr@mail.mil  
Clinical Monitoring and 
Safety Surveillance  US Army Medical Research and Materiel Command  
Office of Regulated Activities  
1430 Veterans Drive Fort Detrick,  
MD 21702 -5009  
Fax: 301 -619-7790  
Telephone: 301 -619-1106  
Institutional Review 
Boards  Walter Reed Army Institute of Research Institutional Review  Board  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9940  
Fax: (301) 319 -9961  
Email: usarmy.detrick.medcom -wrair.mbx.hspb@mail.mil  
USAMRMC Office of 
Research Protections  Human Research Protection Office  
US Army Medical Research and Materi el Command  
ATTN: MCMR -RPH  
504 Scott Street  
Fort Detrick, MD 21702 -5012  
Fax: 301 -619-7803  
Telephone: 301 -619-2165  
Email: usarmy.detrick.medcom -usamrmc.other.hrpo@mail.mil  
 
FOR OFFICIAL USE ONLY 
Information and data included in this document contain privileged and/or proprietary information, which is the 
property of the United States Army. No person is authorized to make it public without express written permission of 
the United States Army. These restrictions on disclosure will apply equally to all future information, which is 
indicated as privileged or proprietary. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 6 US Gove rnment Proprietary INVESTIGATOR’S AGREEMENT 
 
Bridging Trial to Evaluate the Infectivity Equivalence of Current and New Lots of 
Plasmodium falciparum  strain NF54 (clone 3D7) within the WRAIR Controlled Human 
M
alaria Infection (CHMI) Model 
 
“I have read this protocol and agree to conduct the study as outlined herein in accordance with 
International Conference on Harmonization Good Clinical Practice Guideline and FDA, DoD, 
and United States Army Regulations.” 
   
James E. Moon, MD,  COL, MC, USA  
Principal Investigator  
Malaria Vaccine Branch  
Walter Reed Army Institute of Research   Date  
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 7 US Gove rnment Proprietary EMERGENCY CONTACT INFORMATION 
Table 1: Emergency Contact Information  
Role in Study  Name  Address and Telephone Number  
Principal Investigator  James E. Moon, COL, MC, 
USA  Malaria Vaccine Branch (MVB)  
Walter Reed Army Institute of 
Research (WRAIR)  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9176  
Fax: (301) 319 -9449  
Email: James.e.moon.mil@mail.mil  
Subinvestigators : Paige Waterman  COL, MC, 
USA   Telephone: 301 -319-9312  
Email:  
Paige.e.waterman.mil@mail.mil  
 Judith Epstein  CAPT, MC, 
USN  Telephone: 301 -319-7686  
Email: Judith.e.epstein.mil@mail.mil  
 Melinda Hamer  LTC, MC, 
USA  Telephone: 301 -319-3136   
Email: Melinda.j.hamer.mil@mail.mil  
 Christine Lee, MD  Telephone: 301 -319-9650  
Email: Christine.e.lee12.ctr@mail.mil  
 Julie Ake LTC, MC, USA  Telephone: 301 -500-3621  
Email: jake@hivresearch.org   
 Justin Curley LTC,  MC, 
USA  Telephone: 301 -319-9687  
Email:Justin.m.curley.mil@mail.mil  
 Ilin Chuang CAPT, MC, 
USN  Telephone: 301 -319-9786  
Email: Ilin.chuang.mil@mail.mil  
 Michael Koren MAJ, MC, 
USA  Telephone: 321 -319-9904  
Email: 
Michael.a.koren2 .mil@mail.mil  
 Jesse DeLuca LTC, MC, 
USA  Telephone: 301 -319-9418  
Email: Jesse.p.deluca.mil@mail.mil  
 Daniel J. Selig  CPT, MC, 
USA  Telephone: 301 -319-9931  
Email: Daniel.j.selig.mil@mail.mil  
 Jack N. Hutter  MAJ, MC, 
USA  Telephone: 301 -319-3095  
Email: Jack.n.hutter.mil@mail.mil  
 Viseth Ngauy, COL, MC, 
USA  Tel: (301) 319 -9389  
Email: viseth.ngauy.mil @mail.mil  
   
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 8 US Gove rnment Proprietary Role in Study  Name  Address and Telephone Number  
Research Monitor  Ramiro Gutierrez , MD  
CAPT, MC, USN  
 NMRC  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: 301-319-3193  
Email: 
Ramiro.l.gutierrez.mil@mail.mil  
Ombudsman  Michael Hrycyk  Walter Reed Army Institute of 
Research  
Telephone: 301 -319-2002  
Office of Regulated 
Activities Product Safety 
and Surveillance Branch  Teresa Deal, RN  USAMRMC  
1430 Veterans Drive  
Ft. Detrick, MD 21702 -5009  
Fax: 301 -619-7790  
Telephone: 301 -619-1005  
Sponsor’s Representative  Mark Paxton  USAMRMC  
1430 Veterans Drive  
Ft. Detrick, MD 21702 -5009  
301-619-0317  
Email: Mark.s.paxton.civ @mail.mil  
Institutional Review Board  WRAIR IRB  
 WRAIR IRB  
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Tel: (301) 319 -9940  
Fax: (301) 319 -9961  
Email: usarmy.detrick.medcom -
wrair.mbx.hspb@mail.mil   
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 9 US Gove rnment Proprietary 2. SYNOPSIS 
Name of Sponsor : 
The Surgeon General, Department of the Army  
Name of Investigational Product : 
Mosquitoes (female Anopheles ) infected with Plasmodium falciparum  strain NF54  (clone 3D7)  
(lot 1887)  
Title of Study:  
Bridging Trial to Evaluate the Infectivity Equivalence of  Current and New Lots of Plasmodium 
falciparum strain NF54 (clone 3D7) within th e WRAIR Controlled Human Malaria Infection (CHMI) 
Model  
Study Center(s):  WRAIR  Clinical Trials Center  
Principal Investigator:  
James E. Moon, COL, MC, USA   
Study  Period (years):  
Estimated date first subject enrolled: February 2019  
Estimated date last subject completed: May 2019  Phase of development:   
Not applicable  
Objectives:  
Primary:  
 To characterize the infectivity of the new lot  (1887)  of Plasmodium falciparum  strain NF54 
(clone 3D7)within the standard WRAIR CHMI model   
Secondary:  
 To assess  safety of the new lot of  P falciparum parasites  
 To assess the kinetics of detecting parasitemia and parasite clearance by quantitative polymerase 
chain reaction (qPCR) as compared to blood smear as part of the process of validating the  assay 
for future use  
 To obtain plasma samples to restore the testing control pool for malaria serology testing and for 
future malaria research  
Methodology:  
This is a single center, open label CHMI study. C HMI  will consist of exposure to Plasmodium 
falciparum  sporozoites through the bites of infected mosquitoes.  Beginning 5 days  after the challenge, 
subjects will be evaluated daily for the development of malaria infection using a  blood smear . Unless 
previously diagnosed and fully treated, subjects will be  required to stay in a hotel for a maximum of 
10 nights starting on or around the evening of Day 9 post challenge.  
All subjects diagnosed with malaria infection based on smears will be prescribed a standard malaria 
treatment regimen to begin on the day th at parasitemia is detected. Subjects who do not become 
parasitemic (via smear) by Day 19 will be empirically treated for malaria.  
After the hotel phase, all challenged subjects will have a final scheduled follow -up visit on Day 28 
(±7 days).  
Estimated Number of Subjects Screened:  
Up to 50  
Maximum Number of Subjects Enrolled:  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 10  US Government Proprietary 12 (Enrollment defined as receipt of malaria challenge)  
Main Criteria for Inclusion/Exclusion:   
Healthy adults, aged 18 -50, military or civilian, males or non -pregnant,  non-lactating females, who 
are able to give informed consent, understand the risks and benefits of the study and understand and 
are willing to comply with all protocol procedures and time commitments  
Investigational Product Dosage, Schedule, and Mode of Administration:  
Laboratory cultured Plasmodium falciparum  strain 3D7 delivered via the bite of 5  infected 
mosquitoes with salivary gland scores of at least 2+ (11 -100 sporozoites observed) . 
Duration of Treatment:  
Up to approximately 3 months for all sub jects: up to 2 months for recruitment and screening, and 
1 month for challen ge and post -challenge follow -up. 
Criteria for Evaluation:  
Infective Efficacy:  
• Proportion of challenged subjects exposed to the new lot of Plasmodium falciparum  strain 3D7 
parasites developing parasitemia  (defined as 2 unambiguous  malaria  parasites on a single 
smear).  
Diagnostic Efficacy:  
• Time to parasitemia by blood smear after the P falciparum  challenge  
• Time to parasitemia by qPCR after the P falciparum  challenge  
• Quantification of parasite clearance time (PCT) by blood smear after initiation of antimalarial 
treatment  
• Quantification of parasite clearance time (PCT) by qPCR  after initiation of antimalarial 
treatment  
Safety:  
• Occurrence of related unanticipated problems involving risk to subjects or others, adverse 
events, serious adverse events, and/or pregnancies at any time during the study period 
(enrollment to final follow -up visit)  
Statistical M ethods:  
The proportion of subjects with parasite mia will be compared against the historical efficacy rate. No 
formal hypothesis testing will be conducted and all statistics  will be descriptive in nature. This data 
will be the start of a series of trials used to conduct a more formal non -inferiority meta -analysis. The 
frequency of Adverse Events will be presented. Secondary Objectives will be evaluated by describing 
the time to parasitemia and the parasite clearance times. A formal statistical analysis plan will be 
developed prior to database lock or any analysis of data.   
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 11  US Government Proprietary 3. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS 
1. T ITLE PAGE ................................................................................................ .............1 
I
NVESTIGATOR’S AGREEMENT ...............................................................................................6 
2. S YNOPSIS ................................................................................................ .................9 
3. TA BLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ............11 
4. LI ST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................15 
5. I NTRODUCTION ................................................................................................ ....17 
5.1. B ackground ..................................................................................................17 
5.2. R ationale for Study ................................................................ .......................17 
5.3. Mil itary Relevance ................................................................ .......................18 
5.4. Na me and Description of the Investigational Product ..................................18 
5.5. S ummary of Nonclinical and Clinical Trials ................................ ................18 
5.5.1.  Nonc
linical Studies ................................................................ ..........18 
5.5.2.  C
linical Studies ................................................................ ................19 
5.6. Know n and Potential Risks and Benefits to Human Subjects ......................20 
5.6.1.  R
isks/Discomfort to Subjects and Precautions to Minimize 
Risk ................................................................................................ ...20 
5.6.1.1. R isks Associated with the Challenge .............................20 
5.6.1.2. R isks Associated with Malaria Treatment .....................21 
5.6.1.2. P regnancy ................................ ................................ .......21 
5.6.1.3. L actation ................................ ................................ .........22 
5.6.1.4. Ve nipuncture ..................................................................22 
5.6.1.5. Aller gic Reaction ................................ ............................22 
5.6.1.6. Unknow n Risks ................................ ..............................22 
5.6.2.  Alter
natives to this IND Product or Study ................................ .......22 
5.6.3.  I
ntended Benefit for Subjects ................................ ...........................22 
5.6.4.  R
isks to the Study Personnel and the Environment .........................22 
5.7. R oute of Administration, Dosage Regimen, Treatment Period, and 
Justification ..................................................................................................23 
5.8. C ompliance Statement ................................................................ ..................24 
5.9. S tudy Population ................................................................ ..........................24 
5.10. S tudy Site ................................................................ ................................ .....24 
6. TR IAL OBJECTIVES AND ENDPOINTS ................................ .............................24 
6.1. Obje ctives ................................................................ ................................ .....24 
6.1.1.  P
rimary Objective ................................................................ ............24 
6.2. Endpoint s ................................................................ ................................ ......25 
6.2.1.  P
rimary Endpoints ................................................................ ............ 25 
6.2.2.  Secondary Endpoints ................................................................ ........25 
7. TR IAL DESIGN ................................................................................................ ......25 
7.1. Ove rall Study Design ................................................................ ...................25 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 12  US Government Proprietary 7.2. Me asures Taken to Minimize/Avoid Bias ................................ ....................30 
7.2.1.  R
andomization ................................................................ .................30 
7.2.2.  B
linding ................................................................ ............................30 
7.3. I nvestigational Product ................................................................ .................30 
7.3.1.  I
nvestigational Product Storage ................................ .......................30 
7.3.2.  I
nvestigational Product Preparation ................................ .................30 
7.3.3.  I
nvestigational Product Accountability ................................ ............30 
7.4. Dur ation of Subject Participation .................................................................31 
7.5. S tudy Termination Criteria ................................ ................................ ...........31 
7.6. I dentification of Data to be Recorded on the Case Report Forms ...............31 
8. S ELECTION AND WITHDRAWAL OF SUBJECTS ................................ ...........31 
8.1. R ecruitment of Subjects ................................................................ ...............31 
8.2. I nformed Consent Process ................................................................ ............32 
8.3. Elig ibility Screening ................................................................ .....................33 
8.3.1.  S
ubject Inclusion Criteria .................................................................34 
8.3.2.  S
ubject Exclusion Criteria ................................................................35 
8.4. C ontraindications to Challenge ................................ ................................ ....37 
8.5. S ubject Withdrawal Criteria ................................ ................................ .........37 
8.5.1.  W
hen and How to Withdraw Subjects ................................ .............37 
8.5.2.  Da
ta Collected for Withdrawn Subjects ................................ ...........38 
8.5.3.  R
eplacement of Subjects ..................................................................38 
8.5.4.  F
ollow-up for Withdrawn Subjects ................................ ..................38 
9. TREATMEN T OF SUBJECTS ................................................................ ...............38 
9.1. Ma laria Challenge ................................................................ ........................38 
9.2. De termination of Parasitemia ................................ ................................ .......38 
9.3. Ma nagement of Challenged Subjects ................................ ...........................39 
9.4. Ma laria Treatment ................................................................ ........................40 
9.5. S tudy Completion ................................................................ .........................41 
9.6. C oncomitant Medications ................................................................ ............41 
9.7. P rocedures for Monitoring Subject Compliance ................................ ..........41 
10. S AFETY ASSESSMENT ................................................................ ........................41 
10.1. Adve rse Event Definitions ................................ ................................ ...........42 
10.1.1.  Adve
rse Event or Suspected Adverse Reaction ...............................42 
10.1.2.  S
olicited Adverse Event ................................................................ ...42 
10.1.3.  Serious Adverse Event or Serious Suspected Adverse 
Reaction ................................................................ ............................43 
10.1.4.  Une
xpected Adverse Event or Unexpected Suspected 
Adverse Reaction ................................................................ .............43 
10.1.5.  Una
nticipated Problems Involving Risks To Subjects Or 
Others ...............................................................................................43 
10.2. Adve rse Event Relationship to Investigational Product ...............................44 
10.3. Adve rse Event Severity Assessment ................................ ............................44 
10.4. R ecording Adverse Events ................................ ................................ ...........45 
10.4.1.  Me
thods/Timing for Assessing, Recording, and Analyzing 
Safety Endpoints ................................................................ .............. 45 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 13  US Government Proprietary 10.4.2.  Duration of Follow-Up of Subjects after Adverse Events ...............46 
10.5. R eporting Adverse Events ................................................................ ............46 
10.5.1.  R
eporting Serious and Unexpected Adverse Events ........................46 
10.5.1.1. R eporting to the Sponsor ................................ ................46 
10.5.1.2. R eporting to the IRB ................................ ......................48 
10.5.2.  R
eporting Additional Immediately Reportable Events to the 
Sponsor’s Safety Office, the IRB, and/or the USAMRMC 
ORP ..................................................................................................48 
10.5.2.1. P regnancy ................................ ................................ .......48 
10.5.2.2. AE- related Withdrawal of Consent ................................49 
10.5.2.3. P ending Inspections/Issuance of Reports .......................49 
10.5.3.  Annua
l and Final Reports .................................................................49 
10.5.4.  I
ND Annual Report to the FDA ................................ .......................49 
10.5.5
. F inal Report ................................................................ ......................49 
11. S TATISTICS ................................................................................................ ............50 
11.1. De scription of Statistical Methods ...............................................................50 
11
.1.1. Ana lysis Addressing the Primary Study Objective ..........................50 
11.1.2.  Ana
lysis Addressing the Secondary Study Objective ......................51 
11.1.2.1. Time to P arasitemia ................................ ........................51 
11.1.2.2. Time to C learance ................................ ..........................51 
11.1.3.  S
afety Analysis ................................................................ .................51 
11.2. P lanned Enrollment and Reason for Sample Size ................................ ........51 
11.3. L evel of Significance to be Used .................................................................52 
11.4. S tatistical Criteria for the Termination of the Trial ................................ ......52 
11.5. Ac counting for Missing, Unused, and Spurious Data ..................................53 
11.6. P rocedures for Reporting Deviations from the Original Statistical 
Plan ................................................................................................ ...............53 
11.7. S election of Subjects to be Included in Analyses ................................ ........53 
12. AD MINISTRATIVE ................................................................................................53 
12.1. Ethi cs ................................................................................................ ............53 
12.1.1.  Ethi
cs Review/Institutional Review Board ................................ ......53 
12.1.2.  C
onfidentiality ................................................................ ..................53 
12.1.3.  C
ompensation for Participation ................................ ........................54 
12.1.4.  Me
dical Care for Research-Related Injury ................................ .......55 
12.1.5.  Written Informed Consent ................................................................ 55 
12.2. P rotocol Approval and Modification ................................ ............................56 
12.2.1.  R
eview/Approval of Study Protocol ................................ ................ 56 
12.2.2.  Protocol Modifications ................................................................ .....56 
12.2.3.  P
rotocol Deviation Procedures ................................ ......................... 57 
12.3.  Sample and Data Handling ................................ ................................ ...........57 
12.3.1.  S
ample Handling and Management ................................ .................58 
12.3.2.  Da
ta Management ............................................................................ 59 
12.3.3.  Retention of Records ................................................................ ........59 
12.4. S tudy Monitoring ................................................................ .........................59 
12.5. Audits  and Inspections ................................................................ .................60 
12.6. Ac cess to Source Data/Documents ................................ ..............................60 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 14  US Government Proprietary 12.7. R eports ................................................................ ................................ .........60 
12.7.1.  Annua
l and Final Reports .................................................................60 
12.7.1.1. I ND Annual Report to the FDA ................................ .....60 
12.7.1.2. F inal Report ................................ ....................................61 
12.7.2.  I
RB Reports ................................................................ ......................61 
12.7.2.1. C ontinuing Review Reports ................................ ...........61 
12.7.2.2. C loseout Report ................................ ..............................61 
13. P UBLICATION POLICY ................................................................ ........................61 
14. LI ST OF REFERENCES ................................................................ .........................62 
15. APP ENDICES ................................................................................................ ..........63 
APP
ENDIX A.  RECRUITMENT SCRIPT ................................ ................................ ...........64 
APP
ENDIX B.  INFORMED CONSENT COMPREHENSION ASSESSMENT ................69 
APP
ENDIX C.  NHANES I CARDIOVASCULAR RISK CRITERIA ................................72 
APP
ENDIX D.  TOXICITY GRADING SCALE FOR ADVERSE EVENT S 
F
OLLOWING MALARIA CHALLENGE ................................ .............................74 
 
LI
ST OF TABLES 
Table 1:  Emergency Contact ................................................................................................ .......7 
Ta
ble 2:  Summary of Infectivity Controls in Clinical Trials using NF54 (clone 3D7) 
lot 0285 ................................................................................................ .......................19 
Ta
ble 3:  Study Events Schedule for the Pre-challenge Phase ................................ ...................26 
Ta
ble 4:  Study Event Schedule for Challenge Phase ................................................................28 
Ta
ble 5:  Investigational Product ...............................................................................................30 
Ta
ble 6:  Adverse Event Relationship to the Investigational Product Categories .....................44 
Ta
ble 7:  Adverse Event Severity Grading Scale ................................................................ .......45 
Ta
ble 8:  Study Contacts for Reporting Serious Adverse Events and Unanticipated 
Problems Involving Risk to Patients or Others ................................ ...........................47 
Ta
ble 9:  SAE Information to be Reported to the Sponsor's Safety Office ...............................48 
Ta
ble 10:  Cumulative Probability of Experiencing Failure and Efficacy Rates .........................52 
Ta
ble 11:  Width of Confidence Intervals for Frequency of Adverse Events .............................52 
 
LI
ST OF FIGURES 
Figure 1:  NH ANES I Cardiovascular Risk Criteria for Males ................................ ...................72 
F
igure 2:  NH ANES I Cardiovascular Risk Criteria for Females ................................ ...............73 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 15  US Government Proprietary 4. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  Explanation  
β-HCG  Beta-human chorionic gonadotropin  
AE Adverse event  
AI Associate investigator  
AL Artemether/lumefantrine (Coartem)  
ALT  Alanine aminotransferase  
AP Atovaquone/proguanil (Malarone)  
AR Army Regulation  
AST  Aspartate aminotransferase  
CBC  Complete blood count  
CHMI  Controlled human malaria infection  
CQ Chloroquine  
CRF  Case Report Form  
CTC  Clinical Trials Center  
DMP  Data management plan  
DoD  Department of Defense  
ECG  Electrocardiogram  
FDA  United States Food and Drug Administration  
GCP  Good clinical practice  
HBV  Hepatitis B virus  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HIPAA  Health Insurance Portability Accountability Act  
HIV Human immunodeficiency virus  
HSPB  Human Subjects Protection Branch  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
MVB  Malaria Vaccine Branch  
NHANES I  National Health and Nutrition Examination Survey I  
NMRC  Naval Medical Research Command  
ORA  Office of Regulated Activities (USAMRMC)  
ORP HRPO  Office of Research Protections, Human Research Protection Office  
PCR  Polymerase chain reaction  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 16  US Government Proprietary Abbreviation  Explanation  
PCT Parasite clearance time  
PI Principal investigator  
PO By mouth  
PSSB  Product Safety Surveillance Branch   
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS® Statistical Analysis Software  
SD Standard deviation  
SEM  Standard error of the mean  
SID Screening/Study Identification  
SOP Standard operating procedure  
SSP Study specific procedure  
TMF  Trial master file  
TSG  The Surgeon General  
UAE  Unexpected Adverse Event  
UPIRTSOs  Unanticipated Problem Involving Risk to Subjects or Others  
USAMRMC  United States Army Medical Research and Materiel Command  
WBC  White blood cell  
WHO  World Health Organization  
WRAIR  Walter Reed Army Institute of Research  
WRNMMC  Walter Reed National Military Medical Center  
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 17  US Government Proprietary 5. INTRODUCTION 
5.1. Background 
Since the introduction of the Trager-Jensen method of culturing Plasmodium  falciparum malaria 
in 19
76, 3D7 and its parental line, NF54, have been used in experimental human malaria 
infections. From 1989 to 1995, clinical trials at WRAIR used research grade parasites grown 
from wor
king stocks used in the laboratory; this included infectivity trials that established the 
5-bite challenge model used in Controlled Human Malaria Infection (CHMI) today ( Rickman et 
al-1990 ). The first isolate of 3D7 to be propagated under cGMP conditions and cryopreserved 
specifically for use in humans was taken in 1995 from a blood collection of a single control 
subject in the NYVAC-Pf7 trial ( Ockenhouse et al-1998 ) who had been infected with research 
grade 3D7 from the bite of an Anopheles stephensi  mosquito. This cryopreserved lot (0285) was 
fir
st used to test RTS,S in immunologically naïve adults ( Stoute et al-1997 ) and has been used in 
53 CHMIs through mid-2018. In early 2010s, it was recognized that Lot 0285 was approaching 
20 years in cryopreservation and CHMI demand would exceed the supply of remaining vials; as 
of April 2018, 13 vials of 0285 remain, 9 of which are reserved for known, near-future CHMI 
trials. 
In 2012, to refresh the cryostock supply, blood draws from 5 control subjects in WRAIR #1853 
(S-11-21; CelTOS trial) were cultured to generate a new cGMP lot. Control subject cultures were 
e
xpanded and each line was screened for mosquito infectivity. Data from 106 mosquito feeds 
determined which line delivered the most robust and reliable infections in mosquito salivary 
glands; this line (from a single donor) was propagated under cGMP conditions in 2014, tested for 
ster
ility and mycoplasma, and submitted to drug sensitivity and whole genome sequencing 
analyses which showed the new lot of NF54 (clone 3D7) (1887) has similar characteristics to lot 
0285 a
nd is identifiable as NF54 (clone 3D7). Based on prevalence and intensity of oocyst and 
sporozoit
e comparative mosquito infections indicated that Lot 1887 was as infectious to 
mosq
uitoes as Lot 0285. Lot 1887 was released for human use in 2017 and has been in 
c
ryopreservation since lot release. This lot (1887) is awaiting comparative infectivity bridging 
studi
es with the current lot, 0285.  
5
.2. Rationale for Study 
The current lot (0285) of P falciparum infected mosquitoes, strain NF54 (clone 3D7)is 23 years 
old (a
s of 2018) and is only anticipated to last through 2019. A new lot (1887) of strain NF54 
(clone 3D7 ), derived from subjects infected with the original lot of infected mosquitoes was 
pre
pared under GMP conditions in 2014 and has been released for use in humans. The proposed 
study is necessary to bridge the 2 lots and demonstrate comparative infectivity in humans. This 
study is required to establish the baseline infectivity for future studies, ensuring continuity and 
comparability of CHMI for vaccine and drug development worldwide.  
I
f the proposed study is not performed, then once the current parasite lot (0285) is expended 
(c
urrently estimated to occur at some point in 2019), the DoD will lose the use of this CHMI 
model, and all future DoD clinical malaria research efforts will be significantly hindered as a 
result. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 18  US Government Proprietary 5.3. Military Relevance 
As there is no known correlate of protection for malaria, all potential prophylactic or therapeutic 
agents must be evaluated in either CHMI or field settings to assess their efficacy. The Military 
population is generally non-immune to malaria, so field trials must use a non-immune 
population. Endemic regions with non-immune populations are difficult to identify or are 
una
vailable making field trials potentially unfeasible. Therefore, the WRAIR CHMI model is a 
critica
l tool in continuing DoD research efforts to protect the Warfighter from malaria.  
5.4. Name and Description of the Investigational Product 
The investigational product for this study is Anopheles stephensi  mosquitoes infected with 
l
aboratory cultured P falciparum  strain NF54 (clone 3D7), lot 1887. The 3D7 clone of 
P
 falciparum strain NF54 is a human malaria isolate that has never been passed through 
monkey
s and is well adapted to culture. It is a good producer of gametocytes that can infect 
mosq
uitoes, it is s usceptible to FDA-approved antimalarial treatment readily available in the 
United States, and has previously been used in various CHMI clinical trials to successfully infect 
human subjects under a Biologics Master File (BMF-5855) submitted to the FDA. Master seed 
lot
s of these parasites have been developed under GMP conditions and stored at WRAIR. All 
blood products used for malaria and mosquito culturing will be commercially tested for HIV, 
HBV, HCV, HTLV1/2, West Nile Virus, Trypa nosoma cruzi (Chagas disease), and syphilis. The 
mosquitoes used will be laboratory born and reared Anopheles stephensi . This species is 
relatively easy to maintain in the laboratory for up to 21 days after infection with malaria and 
the
y feed readily on humans and are able to transmit malaria to subjects. Over 1,000 subject s 
ha
ve been challenged at WRAIR and NMRC using the current lot (0285) of strain NF54 (clone 
3D7) without
 requiring a single inpatient admission as a result of malaria infection.  
The original seed lot (0285) and the replacement seed lot (1887) were shown in parallel standard 
membrane feeding assays to equivalently infect laboratory reared A stephensi . Whole genome 
sequencing of both lots compared against the reference 3D7 genome database reported the lots to 
be genetically identical. The drug sensitivity profiles of both lots are the same. 
The
 NF54 strain (clone 3D7) and its use is described in BMF 5855 held by The Surgeon General, 
Department of the Army. Information on the provenance and testing of both lots are contained 
within the master file. 
5.5. Summary of Nonclinical and Clinical Trials 
5.5.1. Nonclin ical Studies 
NF54  (clone 3D7) is one of the most widely used laboratory-cultured P falc iparum  strains in the 
wor
ld. It is considered a canonical reference strain for all fields of P falciparum  research. 
L
ot 1887 in particular was tested for viability upon thaw from cryostock, growth in culture 
(inc
reased parasitemia, appearance of gametocyte forms, exflagellation) and for A stephensi  
infectivity (oocyst infection prevalence and intensity in midguts and sporozoite prevalence and 
rating in salivary glands). For all measures tested, Lot 1887 met standards and was comparable 
to Lot 0285. Specific data from these studies are contained within BMF 5855. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 19  US Government Proprietary 5.5.2. Clin ical Studies 
The WRAIR CHMI model has been used for over 30 years, and more than 1,500 subjects have 
be
en safely and successfully challenged with this model at WRAIR and NMRC during this time. 
Prior to 1996, NF54 (clone 3D7) CHMIs, including initial infectivity assessments, R32 and 
NYVAC -
Pf7 vaccine efficacy studies, and delivery of irradiated parasites by mosquito bite were 
pe
rformed with mosquitoes infected with research-grade NF54 (clone 3D7) P falciparum. 
L
ot 0285 was derived from a control subject in the NYVAC-Pf7 trial, produced under cGMP 
c
onditions and used in WRAIR CHMIs until present day. Recent clinical studies using NF54 
(clone 3D7) CHMI are summarized in Table 2. Current methods of infected mosquito production 
ha
ve been in place since 2012. Since then, historical transmission rate to subjects receiving bites 
fr
om 5 mosquitoes infected with NF54 (clone3D7) lot 0285 without antimalarial prophylaxis is 
95.1% (range 83.3-100%). 
Tab
le 2: Summary of Infectivity Controls in Clinical Trials using NF54 (clone 3D7) lot 
0285 
Study identifier(s)  Challenge 
Date  Total 
Subjects 
Challenged  Control 
Subjects  Malaria Positive 
Control Subjects  
CelTOS 2012  
(WRAIR #1853; S -11-21) Aug 2012  35 6 5/6 
CelTOS 2015  
(WRAIR #2113; S -14-02) Mar 2015  29 6 6/6 
VRC312 (NIH 11 -1-0257)  Oct 2012  22 6 5/6 
Feb 2013  22 6 6/6 
VRC314  
(WRAIR #2101; NIH 14 -1-0035; BB -
IND-14826)  Jun 2014  15 6 6/6 
Sep 2014  38 6 5/6 
Oct 2014  15 6 5/6 
Feb 2015  38 6 6/6 
Jul 2015  18 6 5/6 
Oct 2015  20 6 6/6 
Warfighter I  
(WRAIR #2080; NMRC2014.004; 
BB-IND-14826)  Nov 2014  35 6 6/6 
Apr 2015  31 6 6/6 
MAL034 (with Oxford University)  Jul 2012  36 12 12/12  
MAL071 (WRAIR #2007; BB -IND-
12937)  Feb 2014  58 12 12/12  
Sep 2014  37 6 6/6 
MAL092 (WRAIR #2345; BB -IND-
12937)  Jun 2018  128 24 22/24  
(6/6, 5/6,  6/6, 
5/6) 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 20  US Government Proprietary Study identifier(s)  Challenge 
Date  Total 
Subjects 
Challenged  Control 
Subjects  Malaria Positive 
Control Subjects  
VAC045 (with Oxford University)  Jun 2013  30 6 6/6 
VAC055 (WRAIR #2114; with 
Oxford University)  Nov 2013  45 6 6/6 
May 2014  24 6 6/6 
VAC059 (WRAIR #2201; with 
Oxford University)  Mar 2015  52 6 6/6 
VAC065 (WRAIR #2388; with 
Oxford University)  Jan 2017  50 6 6/6 
Sep 2017  40 6 5/6 
5.6. Known and Potential Risks and Benefits to Human Subjects 
5.6.1.  Risks/Discomfort to Subjects and Precautions to Minimize Risk 
Outlined below are anticipated and unexpected adverse reactions, and a brief description of 
procedures to ameliorate risks and symptoms. All known risks and precautions described here 
a
re explained in detail in the informed consent. 
5.6.1.1. Risks Associated with the Challenge 
Risks associated with malaria challenge include local inflammatory reactions to mosquito bites 
and the development of malaria infection. 
The adverse events that might reasonably be expected to occur in subjects who are exposed to 
mala
ria infection via the WRAIR CHMI model include, but are not necessarily limited to: 
 P ruritus at the challenge site  
 Ta chycardia 
 F ever (oral temperature ≥ 100.4°F/38°C) 
 F everishness (subjective) 
 He adache 
 Fatigue 
 Malaise 
 Chills 
 Sweats 
 Arthralgia 
 M yalgia  
 Gastrointestinal symptoms (nausea/vomiting/diarrhea/abdominal pain) 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 21  US Government Proprietary Three cardiovascular events (1 myocardial infarction, 1 myocardial infarction vs. myocarditis, 1 
m
yocarditis) in 3 different subjects have been described at Radboud University Nijmegen 
Me
dical Center (RUNMC) in subjects participating in clinical trials that include CHMI. While it 
is not possible to definitively rule out a contributory role of the P falciparum  CHMI, a causal 
a
ssociation has never been established. Rather, the cardiovascular episodes that have occurred 
were felt to be coincidental to the CHMI in all 3 cases. Of note, all three of these individuals 
made a complete recovery following treatment. ( V erhage et al-2005, Nieman et al-2009, van 
Meer et al-2014 ) 
There is a possibility of complications resulting from P falciparum infection in subjects who 
a
cquire the infection naturally; however, these complications are seen in high grade parasitemia 
following
 delays in diagnosis and treatment. Under the carefully controlled conditions of this 
study and frequent laboratory evaluations to detect active infection, the chance of serious illness 
or death from malaria infection is minimal. During previous studies that included CHMI studies 
a
t WRAIR and NMRC, involving P fal ciparum and more than 1,500 subjects, there has never 
be
en a mortality or episode in which a subject required hospitalization. In addition, no individual 
undergoing a NF54 (Clone 3D7) P falciparum  challenge has ever had complicated, severe, or 
re
current malaria. Recently, a potential recurrence, still under evaluation, did occur in a 
challenge utilizing a different strain of malaria. However, based on three decades of use, this is 
still not an expected result from challenge with NF54(Clone 3D7). In the unlikely event that 
malaria were to recur in a trial subject, they would be evaluated and treated as described 
elsewhere in this protocol. 
Transient abnormalities such as fever, headache, mild anemia, thrombocytopenia, leukopenia, 
splenomegaly, hepatic tenderness, and fatigue are known consequences of malaria. In untreated 
cases, malaria infections can lead to kidney, liver, or brain damage, and death. Other risks, 
although highly unlikely, include a systemic allergic reaction to mosquito bites and the chance 
that the mosquitoes may transmit another infectious agent. No previous subject that has 
undergone CHMI using this model/protocol has developed a complication of malaria or has been 
unable to take the prescribed course of oral antimalarial treatment. There are no known cases of 
these mosquitoes transmitting other infectious agents in the context of a trial with CHMI.  
5.6.1.2. Risks Associated with Malaria Treatment 
Additional risks include side effects from antimalarial treatment. 
Subjects who develop malaria infection will be treated with a standard dose of 
atovaquone/proguanil (Malarone; AP); artemether/lumefantrine (Coartem: AL) or chloroquine 
(CQ). AP may cause nausea, vomiting, abdominal pain, upset stomach, headache, diarrhea, 
weakness, loss of appetite, itching and dizziness. AL may cause headache, dizziness, loss of 
appetite, weakness, fever, chills, tiredness, muscle or joint pain, nausea, vomiting, abdominal 
pain, cough, and trouble sleeping. CQ may cause nausea, vomiting, stomach upset, cramps, loss 
of appetite, diarrhea, fatigue, weakness, tinnitus, dizziness, pruritus, rash, or headache. 
5.6.1.2. Pregnancy 
Malaria infection during pregnancy is dangerous to both the pregnant woman and the unborn 
baby; therefore, pregnant females will be excluded from this study. Study subjects should not 
become pregnant during the study and for at least 3 months after the challenge. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 22  US Government Proprietary 5.6.1.3. Lactation 
Malaria is not known to be transmitted via breastfeeding. However, antimalarial agents (like 
most drugs) may transmit to infants via breastfeeding, and some of the agents planned for this 
trial are not recommended for use in infants. As such, lactating females will be excluded from 
participation in the study. 
5.6.1.4. Venipuncture 
Blood sampling carries a minimal risk of minor discomfort and the possibility of minor bruising 
at the site of the needle puncture and, rarely, the possibility of infection at the needle puncture 
site.  
Phlebotomy will be done by trained staff using aseptic technique to reduce the risk of 
complications. The amount of blood loss will be monitored closely to meet the guideline from 
the American Association of Blood Bank that no more than 450 mL  will be collected in any 
8-week period. 
5.6.1.5.
 Allergic Reaction 
Antimalarial drugs will be utilized in this trial, and are unlikely to have ever been used by 
subjects previously. As with any drug administration and no matter what precautions are taken, 
there is always the risk of a serious, or even life-threatening, allergic reaction. Trained medical 
pe
rsonnel and emergency equipment will be available at the trial site to address medical 
emergencies such as anaphylaxis, angioedema, bronchospasm, and laryngospasm. 
5.6.1.6.
 Unknown Risks 
Furthermore, as with all research there is the remote possibility of risks that are unknown or that 
cannot be foreseen based on current information. 
5.6.2. Alte rnatives to this IND Product or Study 
At this time, there is no alternate method to ensure this new lot of parasites is safe and 
predictably infectious in humans. Subjects may choose not to participate in the study. 
5.6.3. In tended Benefit for Subjects 
No direct benefit is intended for study subjects; however, subjects may indirectly benefit from 
general medical evaluation and health screening procedures including testing for HIV, Hepatitis 
B, and Hepatitis C viruses. If they are found to be positive for any infectious diseases other than 
malaria from P falciparum , including HIV, they will be referred to their primary physician where 
they will receive counseling and further medical attention earlier than if they did not know of 
their disease status. Society as a whole may benefit from information learned through this study, 
and in particular from future malaria research studies enabled by this new lot of parasites. 
5.6.4.  Risks to the Study Personnel and the Environment 
The principal risk in the clinical setting is the handling of needles that may be contaminated with 
blood or body fluids and the associated risk of acquiring a blood-borne pathogen including HBV, 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 23  US Government Proprietary hepatitis C virus (HCV), and HIV. Adherence to standard operating procedures (SOP) for 
working with infectious agents and universal precautions will reduce the risk of exposure.  
There are no known risks to the environment other than those associated with the generation of 
biohazardous waste. All biohazardous waste will be disposed of as stipulated by local, state, and 
F
ederal regulations and in accordance with study site SOPs. 
The Investigative staff members who are in the WRAIR insectary during the malaria challenge 
have a small risk of exposure to malaria. This small risk is greatly minimized by following 
stringent insectary SOPs regarding the handling of mosquitoes, the execution of the mosquito 
c
hallenge, and physical movement inside the insectary. 
The risk of accidentally transmitting malaria to a person in the community will be negligible 
because of the following factors/measures: 
 The  infected mosquitoes will be raised in the secure insectary at WRAIR 
 All m alaria challenges occur in the secure insectary 
 The  infected mosquitoes never leave the secured insectary area at any time 
 Ma laria infections in subjects will be treated promptly, before gametocytes can 
develop (generally 10 days after the development of patent malaria), further 
decreasing any risk of transmission to local mosquitoes 
 Ma laria cannot be transmitted person- to-person (ie, it is not contagious) 
5.7. Route of Administration, Dosage Regimen, Treatment Period, and 
Justification 
The malaria challenge will be conducted according to Walter Reed Army Institute of Research 
(WRAIR) standard operating procedures. Briefly, mosquitoes infected via membrane feeds prior 
to challenge and containing sporozoites in their salivary glands will be allowed to feed on the 
subjects. For each subject, 5 mosquitoes will be initially allowed to feed. After 5 minutes of 
exposure to the subject’s arm, the midgut and salivary gland of each of the 5 mosquitoes will be 
im
mediately dissected to confirm the presence of a blood meal and to determine the infectivity 
ra
te and the salivary gland score. The salivary gland score is a measure of the number of 
sporozoites observed under a microscope in media after crushing the mosquito salivary glands. 
Glands are scored according to a logarithmic scale: 0 = no sporozoites; 1 = 1-10 sporozoites; 2 = 
11-100 sporozoites; 3 = 101-1000 sporozoites; 4 = >1000 sporozoites. A mosquito must pass two 
c
riteria to be accepted as a qualifying bite: visual confirmation of blood in the midgut and a 
gland score of 2 or greater. Dissectors will document the gland score or “not fed” status of each 
dissected mosquito, count the number of qualifying bites and determine the number of mosquito 
bites still needed to achieve 5 qualifying bites. Another group of mosquitoes of this number will 
then be allowed to feed on the subject. For example, if a subject has infective bites from 
3 mosquitoes in the first feeding (out of the 5 mosquitoes used), then only 2 fresh mosquitoes 
will be used in the second feeding. This cycle will continue until the subject receives a total of 
5 infected mosquito bites from mosquitoes with a minimum 2+ salivary gland score (2+ = 
11-100 sporozoites observed), the supply of prepared mosquitoes is exhausted, or the volunteer 
re
quests to withdraw from the trial. In the unlikely event that one of the last two options occurs, 
the subje
ct will be treated empirically for malaria and withdrawn from the trial as discussed in 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 24  US Government Proprietary Section 8.5.4 below. Dissectors will review the documentation, verify 5 qualifying bites were 
re
ceived and notify the study investigator. The study investigator reviews the documentation to 
confirm before releasing the subject from the challenge room. ( R ickman et al-1990 ). 
5.8. Compliance Statement 
The study will be conducted according to the protocol and in compliance with International 
Conference on Harmonization (ICH) Good Clinical Practice (GCP), Belmont Principles, and 
other applicable regulatory and Department of Defense (DoD) requirements. All identified study 
personnel will be trained to perform their roles and will carry out their responsibilities in 
a
ccordance with ICH GCP guidelines and the clinic site’s  SOPs. 
5
.9. Study Population 
Up to 12 healthy, malaria-naïve adults, aged 18 to 50 years (inclusive) from the diverse local 
comm
unity of the Greater Metropolitan Washington, DC/ Baltimore area will be enrolled 
(defined as receiving malaria challenge) in the study. Additional subjects may be recruited and 
sc
reened as alternates to ensure 12 subjects are challenged. Based on previous enrollments for 
malar
ia vaccine trials at the WRAIR CTC, it is estimated that at least 3 times the number of 
subjects to be enrolled will need to be screened in order to reach the target number of 12. 
5
.10. Study Site 
The majority of subject visits will occur at the Walter Reed Army Institute of Research 
(WRAIR) Clinical Trials Center (Silver Spring, MD) to include: recruitment, screening, 
enrollment, and certain follow-up visits. Malaria Challenge will occur in the Insectary and 
associated rooms at WRAIR. Post-challenge, subjects will spend some time and have some of 
their
 follow-up visits in a local hotel. 
6. TRIAL OBJECTIVES AND ENDPOINTS 
6.1. Objectives  
6.1.1. P rimary Objective 
 To c haracterize the infectivity of the new lot (1887) of Plasmodium falciparum  strain 
NF
54 (clone 3D7), parasites within the standard WRAIR CHMI model 
6.1.2. Secondary Objectives  
 To assess the safety of the new lot of Plasmodium falciparum  parasites 
 To assess the kinetics of detecting parasitemia and parasite clearance by quantitative 
polymerase chain reaction (qPCR) as compared to blood smear as part of the process 
of validating the assay for future use 
 To obtain plasma  samples to restore the testing control pool for malaria serology 
testing and to acquire samples for future malaria research 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 25  US Government Proprietary 6.2. Endpoints 
6.2.1. P rimary Endpoints 
Infective Efficacy: 
 Proportion of challenged subjects exposed to the new lot of Plasmodium falciparum  
strain NF54 (clone 3D7) developing parasitemia (where parasitemia is defined as the 
presence of 2 unambiguous parasites on a single smear) 
6.2.2. S econdary Endpoints 
Diagnostic Efficacy: 
 Time to pa rasitemia by blood smear after the P falciparum challenge 
 Time to pa rasitemia by qPCR after the P falciparum challenge  
 Qua ntification of parasite clearance time (PCT) by blood smear after initiation of 
antimalarial treatment  
 Qua ntification of parasite clearance time (PCT) by qPCR after initiation of 
antimalarial treatment  
Safety: 
 Occurrence of related unanticipated problems involving risk to subjects or others, 
unexpected adverse events, serious adverse events, and/or pregnancies at any time 
during the study period (enrollment to final follow-up visit) 
7. TRIAL DESIGN 
7.1. Overall Study Design 
This is a single center, open label CHMI study. The trial design is illustrated in Table 3 and 
Table 4 and is detailed below.  
He
althy, malaria-naïve adults (males and non-pregnant, non-lactating females), aged 18 to 
50 years old (inclusive) will be recruited from the Washington/ Baltimore DC metropolitan area 
to par
ticipate in this Controlled Human Malaria Infection (CHMI) study. Up to 12 subjects will 
e
nrolled (defined as having undergone malaria challenge) into this trial. All 12 subjects will be 
c
hallenged with the new lot o f female Anopheles  mosquitoes infected with Plasmodium 
falciparum strain NF54 (clone 3D7), lot 1887. Based on logistical considerations, subjects may 
unde
rgo challenge on multiple sequential days (in groups of 6), or be challenged altogether on 
the same day. Additional subjects may be recruited and screened as alternates to ensure that 
12 subjects undergo challenge. Any alternates not challenged will be released from the study on 
the 
day of challenge. 
Challenge will consist of exposure to Plasmodium falciparum sporozoites through the bites of 
infe
cted mosquitoes. Beginning on Day 5 and going through Day 19 after the challenge, subjects 
will be
 evaluated daily for the development of malaria infection (defined as the presence o f 
2 unambiguous malaria parasites on a single smear) utilizing blood smear. In addition to smears, 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 26  US Government Proprietary subjects will also be evaluated for the presence of parasitemia via qPCR. However, only blood 
smears will be used for diagnosis during this trial. Testing by qPCR will be performed beg inning 
on Day of Challenge (Day 0) through approximately Day 19 after challenge.. On Day 0, subjects 
will be evaluated by qPCR once prior to challenge, to establish a baseline. From Day 1 through 
a
pproximately Day 19 subjects will be evaluated by qPCR onc e da ily. In the unlikely event a 
subject is diagnosed with malaria prior to Day 9, they will be treated as an outpatient, with the 
loca
tion of those outpatient visits (WRAIR CTC vs. Hotel) to be determined on a case- by-case 
basis. Otherwise, subjects that have not been previously diagnosed will be required to stay in a 
hotel f
or a maximum of 10 nights starting on or around the evening of Day 9 post challenge.  
All su
bjects diagnosed with malaria infection based on blood smears will be prescribed a 
standard treatment regimen consisting of atovaquone-proguanil (AP; Malarone®), 
artemether/lumefantrine (AL; Coartem®) or chloroquine (CQ), atovaquone-proguanil, to begin 
on the day that parasitemia is detected. Subjects who do not become parasitemic by Day 19 will 
be empirically treated using a standard regimen for malaria. 
For purposes of confirming treatment effectiveness, daily blood smears will be continued after 
diagnosis until 3 consecutive negative smears have been documented. Negative smears are those 
which do not meet the criteria for parasitemia/positive smear defined elsewhere in this protocol. 
Daily qPCR will be continued until 2 consecutive negative results (separated by approximately 
24 hours) have been determined following at least one positive (qPCR) result, or until smears are 
discontinued, whichever occurs first. If no positive qPCR results occur, then testing will be 
discontinued when smear efficacy criteria are met. If a treated subject has not met the above 
criteria for confirming treatment effectiveness by Day 19, they will be followed daily in the CTC 
for blood draws and continued testing until they meet criteria. 
After the hotel phase, all challenged subjects will have a final scheduled follow-up visit on 
Day 28 (±7 days). 
T
able 3: Study Events Schedule for the Pre-challenge Phase 
Pre-challenge Events  Study Day for All Cohortsa 
-60 to -3 
Visit Number  1 
General Procedures  
Screening, briefing, informed consent documents  ● 
Comprehension assessment  ● 
Full medical history and physical examinationb ● 
Check NHANES I criteriac ● 
Record medications  ● 
Review inclusion criteria  ● 
Review exclusion criteria  ● 
Screening laboratory assays (~35 mL blood)d ● 
Urine -HCG pregnancy test (females only)  ● 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 27  US Government Proprietary Pre-challenge Events  Study Day for All Cohortsa 
-60 to -3 
Visit Number  1 
ECG  ● 
Amount of Blood Volume  
Approximate Blood volume in mL per visit  35 
Approximate Cumulative blood volume for study 
(mL)  35 
a Some or all of the study dates in this section represent a window of dates. 
b Vital signs collected at all study visits. 
c All acronyms defined in the list of abbreviations.  
d Includes complete blood count, creatinine, glucose, AST, ALT, HIV-1/2, hepatitis B surface antigen, hepatitis C 
virus antibody, sickle-cell screening and G6PD. 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
I
ND 17572; S-18-02 De partment of the Army 
Version 3.0 (13FEB2019) 28 US Government Proprietary Table 4: Study Event Schedule for Challenge Phase 
Phase  Challenge  Post-challenge  Post-challenge Hotel Phase  Final Visit  
Study Dayb 0 1c 2 3 4 5 6 7 8 9d 10 11 12 13 14 15 16 17 18 19e 28 ±7 
Visit Number(s)  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
General Procedures e 
Physical examf, g ●                     
Review  medical 
history and 
medications  ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Review 
inclusion/exclusion 
criteria  ●     
                
Review 
contraindications  ●     
                
Urine -HCG 
pregnancy test 
(females only) h ●     
                
Emergency 
notification card 
provided  ●     
                
Sporozoite challenge 
(CHMI)  ●                     
Safety Assessment  
Safety laboratory 
assays (~8  mL) i ●         ●j           ● 
Draw for plasma pools 
and future use 
(50mL)k      
  ●             ● 
Assess for AE/SAEl ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● l 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
I
ND 17572; S-18-02 De partment of the Army 
Version 3.0 (13FEB2019) 29 US Government Proprietary Phase  Challenge  Post-challenge  Post-challenge Hotel Phase  Final Visit  
Study Dayb 0 1 2 3 4 5 6 7 8 9d 10 11 12 13 14 15 16 17 18 19e 28 (±7 days)  
Visit Number(s)  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Diagnostic Assessment  
Smear (2  mL) m, n      ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  
PCR(2  mL)m, n ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  
Blood Volume (mL)  
Approximate blood 
volume per day  10 2 2 2 2 4 4 54 4 12 4 4 4 4 4 4 4 4 4 4 58 
Approximate total 
blood volume  45 47 49 51 53 57 61 115 119 131 135 139 143 147 151 155 159 163 167 171 229 
a Unused alternates will be released from the trial on Day 0. 
b Some or all of the study dates in this section represent a window of dates. In particular, the final study visit will have a +/- 7 day window. 
c PCRs will be performed daily on certain study days (Day 1 through potentially Day 21, depending on when treatment is initiated)  
d Subjects will check in to the hotel on or around the evening of Day 9 post-challenge; the first morning study visit performed in the hotel will be on Day 10. 
e Su
bjects treated empirically on Day 19 will be seen daily for additional blood draws for diagnostics, until successful treatment criteria are met. The additional 
blood draws may increase blood draw volume by up to approximately 20 mL. In this case, the total number of visits may increase up to approximately 25. 
f Vital signs collected at all study visits. 
g Challenge site exam on Day 0. Otherwise, directed physical exam as needed per investigator discretion. 
h All acronyms defined in the list of abbreviations.  
i Safety labs include CBC, creatinine, AST, and ALT. 
j Safety labs will be drawn within approximately 24 hours of the diagnosis of parasitemia, preferably at the time of diagnosis. 
k Future use blood draws will not be collected if subject has not consented to future use of specimens. 
l SAEs and Pregnancies may be followed to resolution past conclusion of the trial if they meet certain criteria 
m Total volume will be 4 mL per draw for diagnostics that will be divided and applied to smear and/or qPCR as appropriate.  
n Blood smears and qPCR assays may be discontinued once the subject has 3 consecutive (daily) negative smears and 2 negative (daily) qPCRs, respectively, 
following the initiation of treatment. If qPCRs remain positive when smear discontinuation criteria are met, then qPCRs will also be discontinued. If qPCRs 
never become positive, they will be discontinued when smears are discontinued. 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 30  US Government Proprietary 7.2. Measures Taken to Minimize/Avoid Bias 
7.2.1. Rand omization 
Randomization will not be used in this study, as all subjects will undergo the same procedures. 
7.2.2. B linding 
Blinding is not applicable and will not be used in this protocol. 
7.3. Investigational Product 
Table 5 presents a summary description of the investigational product. 
T
able 5: Investigational Product 
Product Name  P falciparum infected mosquitoes  (Strain NF54 (clone 3D7), lot 
1887)  
Unit Dose  Qualifying Mosquito bites  (n=5)  
Route of Administration  Mosquito bites  
Manufacturer  WRAIR Entomology  
Lot Number  25Mar19 -LotBridge(1887) -3D7 
Product Indication  For evaluation of controlled human malaria infection (CHMI) 
model  
7.3.1.  Investigational Product Storage 
The infected mosquitoes are stored in mesh-topped cardboard feeding cartons in environmentally 
controlled chambers at 26±1⁰C and 80±5% relative humidity.  
7.3.2. In vestigational Product Preparation 
The A stephensi  female mosquitoes infected with P falciparum strain NF54 (clone 3D7) parasites 
used for the challenge will be reared in the WRAIR insectary. The mosquitoes are fed on human 
washed packed erythrocytes and serum via a glass membrane feeding system that is warmed by a 
circulating water bath. Once the mosquito eggs enter the phase of adult emergence, 
approximately 250 to 300 females are transferred to mesh-topped cardboard feeding carton with 
10%
 sucrose.  
7.3.3. In vestigational Product Accountability 
The Sponsor’s representative maintains ultimate responsibility for product accountability,  but 
has delegated site product accountability responsibility to the principal investigator at WRAIR 
Insectary. The principal investigator is responsible for and will maintain logs of investigational 
product receipt, storage, accountability by subject in controlled access document storage space at 
the study site. The principal investigator may delegate, in writing, this responsibility to another 
individual, but at the study site, the principal investigator is ultimately responsible for the 
investigational product and its proper storage upon receipt at the study site until it is destroyed, 
as directed by the Sponsor’s representative.  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 31  US Government Proprietary All unused or partially used investigational product (in this case, infected mosquitoes prepared as 
described above) will be destroyed by the PI or designee by being incinerated and/or disposed of 
a
s biohazardous waste according to local SOPs, as directed by the Sponsor’s representative and 
as stipulated by local, state, and Federal regulations. Unused or partially used investigational 
product may only be destroyed or transferred after authorization has been received from the 
Sponsor’s representative. 
7.4. Duration of Subject Participation 
Approximately 3 months for all subjects (Up to 2 months for recruitment and screening and 
1 month for challenge and post-challenge follow-up). 
7
.5. Study Termination Criteria 
The PI , research monitor, sponsor’s representative, the IRB,  and/or the USAMRMC ORP, or the 
FDA may stop or suspend the use of this product at any time. 
An
y suspensions to include continuing review lapses, voluntary or involuntary clinical holds, or 
terminations of this research by an IRB, the Sponsor, or regulatory agencies will be reported 
within 48 hours to the IRB of record and the Sponsor’s representative by phone, email, or 
facsimile. 
7.6. Identification of Data to be Recorded on the Case Report Forms 
The electronic case report form (eCRF) data will be transcribed from source documentation. No 
sourc
e data will be recorded directly in the eCRF (ie, without prior written or electronic record of 
data). The transcribed data will be consistent with the source documents or the discrepancies will 
be e
xplained.  
F
or more information on data handling, refer to Section 12.2. 
8. SELEC
TION AND WITHDRAWAL OF SUBJECTS 
8.1. Recruitment of Subjects 
Up to 12 healthy, malaria-naïve adults, aged 18-50 years (inclusive) will be enrolled (defined as 
rec
eiving malaria challenge) in the study. Based on previous enrollments for CHMI studies, it is 
e
stimated that at least 3 times the number of subjects to be enrolled will need to be screened 
(approximately 36) in order to reach the target number of 12. Additional subjects may be 
re
cruited and screened as alternates to ensure that the target number of 12 challenged subjects is 
met.  
R
ecruiting will take place through the WRAIR CTC according to applicable regulations and 
policies (eg, DoD Common Rule, 32 CFR 219 and AR 40-38). The recruitment process will be 
the sa
me for both military and civilian personnel.  
Subjects will not be replaced if they withdraw or are eliminated from the study after having 
undergone CHMI.  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 32  US Government Proprietary Healthy, malaria-naive adult subjects from the locally diverse community of the Greater 
Metropolitan Washington DC/ Baltimore area will be recruited under this protocol when 
approved by the IRB of record. Recruitment materials are presented in Appendix A . C ontact will 
be made with potential subjects by advertising mechanisms such as newspapers, flyers, emails, 
websites, direct emails to all WRAIR staff, postings on public electronic bulletin boards, other 
social media (such as Facebook and Geofencing), and posters aimed at adults living in the 
greater Washington, DC metro region. Email announcements will include information on posters 
excluding any photos unless attached as complete flyer. A version of the recruiting script may 
a
lso be emailed to interested individuals. The CTC also may place generic television 
advertisements recruiting for subject participation in the CTC studies (without mentioning 
specific studies). 
Recruitment may include oral presentations, with approved recruiting material available, at 
events, meetings, and briefings where the desired population may be reasonably expected to 
attend. In accordance with DoD Instruction 3216.02, an ombudsman not directly associated with 
the greater than minimal risk research to be performed will be present during recruitment 
activities involving Service members in a group setting (morning formations, etc.). The 
ombudsman will ensure that “the voluntary involvement or recruitment of the Service members 
is clearly and adequately stressed and that the information provided about the research is clear, 
adequate, and accurate.” Active duty military subjects will require approval from their supervisor 
through their branch director using a signed Statement of Supervisor’s Approval. 
8
.2. Informed Consent Process 
The informed consent process will adhere with applicable regulations and SOP. One of the 
investigators and/or delegated study staff will provide an oral explanation of the study in lay 
terms. Alternatively, an IRB-approved power point presentation or video may be used to instruct 
potential subjects about the study. Questions on the purpose of the protocol, protocol procedures, 
and risks to the subjects will then be solicited. Any question that cannot be answered will be 
referred to the PI or AI. The PI or designee shall give the subjects ample opportunity to inquire 
about details of the study, discuss with other people and ask any questions before dating and 
signing the consent form. Subject information and consent form language will be at a reading 
level fully comprehensible to the potential subjects. No subject should grant consent until he or 
she has had the opportunity to read the informed consent document and questions have been 
answered to his/her satisfaction. Informed consent includes the principle that it is critical the 
subject be informed about the principal potential risks and benefits prior to study participation. 
This i
nformation will allow the subject to make a personal risk versus benefit decision and 
understand the following:  
 P articipation is entirely voluntary  
 Subjects may withdraw from participation at any time 
 Refusal to participate involves no penalty  
 The  subject is free to ask any questions that will allow him/her to understand the 
nature of the protocol 
 A de scription of this clinical trial will be available on http://www.ClinicalTrials.gov, 
as required by US law. The web site will not include information that can identify the 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 33  US Government Proprietary volunteer. At most, the web site will include a summary of the results and can be 
se
arched at any time. 
An a
dditional informed consent document for HIV testing will be signed by all subjects. 
Informed consent will be obtained in accordance with 21 CFR 50, 32 CFR 219, DoD Common 
Rule, and the principles of the Belmont Report prior to initiating any study procedures.  
 I nformation will be given in both oral and written form whenever possible and 
deemed appropriate by the IRB. The written consent document contains the required 
and all applicable optional elements of informed consent as described in 21 CFR 
50.25 (including a full explanation of the possible risks, advantages, and alternate 
treatment options, and availability of treatment in the case of injury). In addition, the 
consent document will comply with DoD policy and regulations.  
 Each subject’s signed informed consent document must be kept on file by the PI for 
possible inspection by regulatory authorities and/or regulatory compliance persons. 
The subjects will receive a copy of the signed and dated written informed consent 
document and any other written information provided to the subjects. 
 The  signed consent document indicates that the subject permits access to research and 
relevant medical records by the sponsor’s representative and by representatives of the 
FDA. The sponsor’s representative will submit a copy of the initial IRB- and 
sponsor’
s representative-approved consent form to the FDA and will maintain copies 
of revised consent documents that have been reviewed and approved by the 
IRB/ethics committee 
Subjects will also be required to pass a short multiple-choice quiz that assesses their 
understanding of this study prior to enrollment ( Appendix B ). Subj ects must achieve a score of at 
least 80% correct on a multiple choice quiz that assesses their understanding of the study; 
subjects will be allowed 2 attempts to pass the quiz of understanding. 
Should the protocol be modified, the consent document will be revised to reflect any necessary 
changes made in the protocol with regard to the content of the subject consent document. If a 
previously enrolled subject is directly affected by the change, the subject will receive a copy of 
the revised informed consent document. The approved revision will be read, signed, and dated by 
the subject. Because the informed consent process is ongoing the PI or AI will be available to 
answer subjects’ questions at any time during the study period. Subjects will be periodically 
reminded about the purpose of the study and the study procedures that will take place during 
future visits. 
8.3. Eligibility Screening 
Subjects who have signed an informed consent document will provide a medical history, undergo 
a physical examination and routine laboratory screening tests and be screened for cardiac risk 
factors using family and personal medical history, blood pressure screening, National Health and 
Nutrition Examination Survey I (NHANES I) criteria ( Appendix C ), a nd an electrocardiogram 
(ECG). ( Gaziano et al-2008 ) Female subjects will provide a urine specimen for a urine 
pregnancy test. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 34  US Government Proprietary Subjects found to be seropositive for HIV-1/2, HBV, or HCV will be counseled by the PI and 
referred to a health care provider for further evaluation. Positive HIV, HBV, or HCV results will 
also be reported by the study team to the Maryland AIDS Administration, Department of Health 
and Mental Hygiene within 24 hours of being confirmed as per Health General Article §18-205. 
I
f a subject is in the military, positive HIV results will be reported by the study team to the 
military preventive medicine servic e. 
Subjects must meet all inclusion criteria and will be excluded from participation if they meet any 
of the exclusion criteria.  
All screening tests will be performed prior to entry into the study and safety labs may be 
repeated during the course of the trial as deemed necessary by the investigators to include 
measurement of plasma concentrations of anti-malarial drugs in the event it becomes necessary 
to validate the challenge model. The medical history, physical examination, and laboratory 
findings for subjects will be recorded in the source screening data documents. Screening labs 
may be repeated at the discretion of the clinical investigator in order to properly evaluate a 
subject as routine labs may be outside normal parameters at a single blood draw due to 
physiologic variability or laboratory error/artifact. Non-clinically significant Grade 1 laboratory 
abnormalities which persist on repeat testing may, at the discretion of the principal investigator, 
be deemed non-exclusionary if they are felt to represent the subject’s normal baseline for that 
test. Vital signs (temperature, pulse, blood pressure) are recorded at screening and all other 
sc
heduled study visits unless indicated otherwise. Concomitant medications are also recorded at 
all study visits.  
8.3.1.  Subject Inclusion Criteria 
Subjects must meet all of the following criteria to be included in the study: 
 He althy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age 
(inclusive) at the time of screening 
 If the subject is female, she must be of non-childbearing potential (ie, either 
surgically sterilized or one year post-menopausal), abstinent or using adequate 
contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; 
diaphragm or condom in combination with contraceptive jelly, cream or foam; 
Norplant® or Depo-Provera®) dur ing this study and must agree to continue such 
precautions until three months after challenge 
 F ree of significant health problems (defined as active or chronic health problems 
ne
gatively impacting normal daily functioning) as established by medical history, 
laboratory, and clinical examination before entering the study 
 Ava ilable and willing to participate in all planned study visits for the duration of 
study (approximately 3 months) 
 W illing to comply with all study procedures, to include but not limited to taking anti-
malarial treatment, and staying in a pre-determined hotel during the designated post-
CHMI follow-up period, if indicated  
 No plans to travel to a malaria endemic area ( http://www.cdc.gov/malaria/map/ ) 
during the course of the study 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 35  US Government Proprietary  W illing to refrain from blood donation during the study and for at least 3 years 
following CHMI. 
 W ritten informed consent must be obtained from the subject before screening 
procedures are performed 
 S ubjects must score at least 80% correct on a multiple-choice quiz that assesses their 
understanding of this study  
 If they do not score 80% on the initial quiz, the protocol information will be 
reviewed with them, and they will have the opportunity to retest 
 If a subject fails to correctly answer 80% of the questions after 2 attempts, he or 
she will be excluded from the study 
 I f a subject is active duty military, he or she must obtain approval from his or her 
supervisor to participate 
8.3.2. S ubject Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the study: 
 Any history of malaria infection.  
 Hist ory of travel to P falciparum endemic areas in the 6 months (168 days) prior to 
da
y of challenge, or planned travel to such areas during the course of the study. 
 Hist ory of long-term residence (>5 years) in an area known to have significant 
transmission of P falciparum (http://www.cdc.gov/malaria/map/) 
 Any history of receiving a malaria vaccine 
 Hist ory of receipt of malaria prophylaxis or treatment during 1 month (28 days) prior 
to da
y of challenge, or planned use during the study period (outside of the drugs 
provided by the study team). 
 Hist ory of use of any antimicrobials or other agents with significant antimalarial 
activity (examples include tetracycline, doxycycline, clindamycin, azithromycin, and 
sulfa drugs) during the 1 month (28 days) prior to day of challenge, or planned use 
during the study period. 
 Use of any investigational or non-registered drug or vaccine within 1 month (28 days) 
preceding the day of challenge or planned use during the study period.  
 C urrent or chronic use of systemic immunosuppressant pharmacotherapy or 
immunomodulators; however, subjects may be allowed to use inhaled steroids or 
topical steroids. 
 P regnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female 
at screening or plans to become pregnant or breastfeed from the time of enrollment 
until three months after challenge 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 36  US Government Proprietary  Aller gy to or use of medications known to interact with all the antimalarial drugs 
(CQ, AP, AL) which may be utilized in this trial. Subjects are not excluded if able to 
safely take at least one of the proposed antimalarial drugs for the trial. 
 S ignificant (eg, systemic) hypersensitivity reactions to mosquito bites (local 
hypersensitivity reactions at the site of mosquito bites are not an exclusion criterion) 
 Positive sickle cell screening test including evidence of sickle cell trait or sickle cell 
anemia (due to its effect on susceptibility to malaria)  
 Hist ory of thalassemia or thalassemia trait (due to its effect on susceptibility to 
malaria), or any other clinically significant (defined as negatively impacting subject 
he
alth and/or normal daily functioning) blood disorder 
 Ac ute or chronic, clinically significant (defined as negatively impacting subject 
he
alth and/or normal daily functioning), pulmonary, cardiovascular, endocrine, 
he
patic, immunological or renal functional abnormality, as determined by history, 
physical examination, or laboratory evaluation 
 C hronic or active neurologic disease including seizure disorder (excepting a single 
febrile seizure of childhood) and chronic migraine headaches 
 Hist ory of cancer (except for basal cell carcinoma of the skin) 
 Abnor mal (clinically significant, defined as suggesting an active medical condition or 
pathol
ogy that could negatively impact subject health and/or normal daily 
func
tioning, as determined by physician investigator) baseline laboratory screening 
tests  
 S eropositive for HIV or HCV or hepatitis B surface antigen (HBsAg) positive 
 Evide nce of increased cardiovascular disease risk, "moderate" or "high", according to 
the National Health And Nutrition Examination Survey I (NHANES I) criteria. Note: 
NHANES I criteria will be applied for all subjects including subjects aged 20-35 
years old. 
 An a bnormal baseline screening electrocardiogram, defined as one showing 
pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; 
any non-sinus rhythm excluding isolated premature atrial contractions; right or left 
bundle branch block; or advanced (secondary or tertiary) A-V heart block. 
 Hist ory of splenectomy  
 He patomegaly, right upper quadrant abdominal pain or tenderness 
 History of psoriasis or porphyria 
 Plan for surgery during the period from enrollment until 3 months post-CHMI, with 
the exception of minor cutaneous procedures  
 S uspected or known current alcohol or drug abuse as determined from the medical 
history or by physical examination 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 37  US Government Proprietary  An y other significant finding that in the opinion of the PI would increase the risk of 
having an adverse outcome from participating in this study 
8.4. Contraindications to Challenge 
If a subject has a minor illness (eg, a mild upper respiratory infection) but does not have a fever 
during
 the pre-challenge assessment, the subject may be challenged at the discretion of the PI (in 
c
onsultation with the research monitor). If the subject is moderately to severely ill with a fever 
(te
mperature greater than or equal to 38.0°C (100.4°F) the subject will not be challenged and will 
be withdrawn from the study.  
Pregnant women cannot be challenged.  
8.5. Subject Withdrawal Criteria 
A subject withdrawal is anyone who has not completed the final study visit. A subject may be 
withdrawn for an AE or SAE resulting in a safety concern, for noncompliance with protocol 
requirements, or for other reasons, such as:  
 C onsent withdrawal, not due to an AE 
 Mig rated/moved from the study area 
 L ost to follow-up 
 S ubject unable to continue with all scheduled visits 
 De ath 
 Other (specify) 
A subject may end his or her participation in the study at any time. If a subject withdraws, the PI 
or designee will make a reasonable effort to determine the reason for the withdrawal from the 
stud
y. 
8.5.1. Wh en and How to Withdraw Subjects 
A subject may end his or her participation in the study at any time. If a subject withdraws, the 
investigator will make a reasonable effort to determine the reason for the withdrawal from the 
study and to complete termination procedures. Telephone calls, registered letters, and email 
c
orrespondence are considered reasonable effort. For subjects leaving the study, a targeted 
examination may be performed, if medically indicated and if permitted by the subject. 
A subject may be withdrawn for an adverse event (AE) or serious adverse event (SAE) resulting 
in a safety concern or for noncompliance with protocol requirements. When a subject withdraws 
due
 to an AE or is withdrawn by the principal investigator due to an AE, the sponsor’s safety 
office, the USAMRMC Office of Regulated Activities (ORA) Product Safety Surveillance 
B
ranch (PSSB), must be notified within 24 hours (usarmy.detrick.medcom-usamrmc.mbx.sae-
re
porting@mail.mil). Investigators must follow specific policy regarding the timely reporting of 
AE
s and SAEs to the IRB (Section 10.5.1.2).  In all cases, the PI will make a reasonable effort to 
complete study termination procedures. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 38  US Government Proprietary If a subject meets withdrawal conditions for a concomitant medication violation or 
noncompliance, this should clearly be stated in the source document and the study termination 
electronic CRF. 
8.5.2. Dat a Collected for Withdrawn Subjects 
All samples and data collected up to the time of withdrawal may be utilized in evaluations and 
analysis for the protocol. The study termination eCRF will be completed with the reason for 
withdra
wal specified. 
8.5.3. Re placement of Subjects 
Subjects will not be replaced after enrollment. 
8.5.4.  Follow-up for Withdrawn Subjects 
If a subject ends his or her participation in the study prior to challenge, the investigator will make 
a reasonable effort to determine the reason for the subject’s withdrawal and record the 
information appropriately. If deemed necessary, the investigator may request the subject come in 
for a final visit to ensure subject safety.  
Clinical follow-up after a challenge is important to ensure the safety of the subject. Subjects who 
withdra
w from the study are required to complete clinical follow-up visits and antimalarial 
treatment for safety purposes. Since untreated malaria infection could have severe consequences 
including death, subjects will be sufficiently counseled for this requirement as indicated in the 
informed consent document and advised not to participate if they do not think they can meet this 
requirement. Withdrawal from the study for any reason will not impact the subject’s medical 
care. 
9. TREATMENT OF SUBJECTS 
9.1. Malaria Challenge 
Visit time and event schedules for the primary malaria sporozoite challenge and follow-up are 
presented in Table 4. 
The
 challenge will be performed according to standard operating procedures (SOPs) maintained 
in the WRAIR Entomology Branch regarding this procedure. The A stephensi  female mosquitoes 
infe
cted with strain NF54 (clone 3D7) P falciparum  parasites used for the challenge will be 
re
ared in the WRAIR insectary. Briefly, each subject will have 5 “infected” mosquitoes feed on 
their forearm for 5 minutes. These same mosquitoes will then be dissected to confirm that they 
were infected and the salivary glands will be scored. If all 5 have not adequately fed and/or are 
not infected with a +2 salivary gland score or better, additional mosquitoes will be allowed to 
feed in 5 minute intervals until a total of 5 infected mosquitoes have fed on the subject. 
9
.2. Determination of Parasitemia 
For this trial parasitemia will be determined by utilizing 2 methods: microscopy of Giemsa-
staine
d thick blood films (smear) and through qPCR. However, only blood smear results will be 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 39  US Government Proprietary utilized for diagnosis and evaluation of treatment success. Both procedures will be performed 
according to draft SOPs by the applicable supporting laboratory identified above. For the 
purpo
ses of this trial, parasitemia will be defined as the presence of 2 unambiguous malaria 
parasites on a single smear. 
All blood films (positive and negative) will be archived for later reexamination and confirmation, 
until the protocol is closed. 
9.3. Management of Challenged Subjects 
The pre-patent period (time between exposure and development of demonstrable parasitemia) for 
P
 falciparum in man normally averages 9 to 12 days. In previous studies, the pre-patent period in 
c
ontrols varied from 7-18 days. The shortest reported pre-patent period in man is 5 days, and the 
long
est is 25 days ( Ballou-1987 ).  
Beginning on Day 1 after their challenge, subjects will be seen and evaluated daily by a study 
investi
gator and blood will be drawn for determination of parasitemia by qPCR. Beginning on 
Day 5 after their challenge, blood from these daily draws will also be utilized to generate blood 
smears. As above, only smear results will be utilized for formal diagnosis and evaluation of 
treatment success. 
If fever or symptoms develop at any time, the subject will be evaluated by the study investigator 
a
nd smears may be done more frequently (every 6 to 12 hours) at the discretion of the 
investi
gator. Likewise, qPCR testing may be performed more frequently than planned (up to 
twice a day) at investigator discretion to evaluate symptomatic volunteers or as part of a safety 
evaluation. A confirmed positive result will be relayed immediately to the on-call 
investigator/study personnel by the microscopists. The infection will be treated early (ie, as soon 
as parasites can be identified on thick smear) according to one of the treatment regimens outlined 
be
low.  
Beginning on Day 9 post-challenge, a group of hotel rooms in the local area will be reserved for 
mala
ria-challenged subjects. The subjects will be required to spend their nights there (or, in the 
case of subjects who work at night, spend sleeping hours there) to allow for more rapid 
assessment of any potential symptoms of malaria during the most likely period of patency. There 
will be an investigator present on-site and available for subject assessment. There will also be 
qualified study personnel on site 24 hours per day during the hotel phase of the study. 
During the hotel phase, all challenged subjects will be assessed on a daily basis in an identical 
manner. An evaluation will be done each morning (headache, muscle aches, etc) and blood will 
be drawn for smear and qPCR. All challenged subjects will be instructed to check in with clinical 
staff by telephone call or in-person each evening during the hotel stay until they are positive for 
malaria. They will be asked if they feel any different since they were seen in the morning. At any 
ti
me required, the on-duty investigator will arrange for the timely production of blood smears, 
along with their examination and interpretation, in order to treat subjects for malaria. Once a 
posi
tive smear is identified, daily blood films will continue to be obtained until 3 consecutive 
films
 are negative (separated by more than 12 hours).  
The
 maximum hotel stay for malaria-challenged subjects should be approximately 10  nights. A 
subject who develops malaria, is treated, and has three consecutive negative malaria smears and 
2 c
onsecutive negative qPCRs (separated by more than 12 hours), will not need to remain in the 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 40  US Government Proprietary hotel. The investigators will be responsible for accounting for any subjects who do not arrive in 
the hote
l during the challenge phase. If required, the investigators will physically locate and treat 
any malaria-infected subject who is unable to maintain the follow-up dictated by this study.  
If infection does not develop by Day 19, the subject will be started on empiric treatment for 
mala
ria, and will be released from the hotel. In such cases, subjects will then be required to 
follow-up at the clinic daily for completion of treatment and blood collection (for smears and 
qPCR) until treatment efficacy criteria (3 consecutive negative smears) have been met.  
Following diagnosis, qPCR will be performed daily until negative results from 2 consecutive 
days (tests separated by more than 24 hours) have been determined following at least one 
positive (qPCR) result, or until smears are discontinued, whichever occurs first. If no positive 
qPCR results occur, then testing will be discontinued when smear efficacy criteria are met. As 
above, treatment efficacy will be based on smear results, not qPCR results. 
All subjects will have a final visit at the clinic Day 28 after challenge. 
9.4. Malaria Treatment 
As soon as a malaria infection is documented in a subject, or a subject reaches Day 19 without 
demonstration of parasitemia, he/she will be treated with standard doses of oral Malarone 
(1 g/400 mg, 4 adult tablets per day for 3 consecutive days) under direct observation. This 
re
gimen has been 100% effective in previous WRAIR and NMRC malaria vaccine studies using 
the same malaria strain as will be used in this challenge model. Such early treatment minimizes 
the risk of developing a complicated malaria infection. Alternatively, a standard oral dosage of 
artemether/lumefantrine (Coartem) of 80 mg/480 mg (4 tablets initial dose, 4 tablets 8 hours 
late
r, and then 4  tablets twice daily for the following 2 days) or chloroquine (a total of 1500 mg 
c
hloroquine base: 600 mg base initially, followed by 300 mg base given approximately 6, 24, 
and 48 hours later) can be used to treat subjects.  
The investigators will have available approved antipyretics, such as acetaminophen and 
ibuprofen, for subjects experiencing fever and myalgias. In addition, other approved medications 
will be available to the investigators, which may include, but are not limited to: ondansetron and 
loperamide (Imodium) to treat other signs/symptoms as necessary. Investigators will always 
assure that subjects do not have underlying allergies or other contraindications to any of these 
medic
ations prior to their use. An alternative antipyretic will be provided if the subject is allergic 
to a prescribed drug. 
It is anticipated that treatment of malaria will be curative, since relapses do not occur after 
adequate treatment of P falciparum  infections. No previous subject infected with NF54 (lot 3D7)  
P fal
ciparum  and treated by WRAIR or NMRC has had a malaria recrudescence or relapse. 
S
ubjects will be advised to contact the principal investigator, and to advise their personal 
ph
ysician of their participation in this malaria study, if fever, headache, or other symptoms 
possibly related to malaria develop at any time within 6 months r after completion of the study. If 
contacted and in their medical judgement deemed appropriate, the principal investigator may 
arrange for diagnostic evaluation for malaria. In the unlikely event that malaria recurs, the 
subject will be retreated one of the study medications as above, or with an alternate anti-malarial 
as determined by the principal investigator. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 41  US Government Proprietary 9.5. Study Completion 
When all the follow-up visits for the study are completed, subjects will be notified that they have 
c
ompleted the study. In addition, subjects who are treated for malaria following challenge will 
not be able to donate blood for 3 years, per the American Red Cross guidelines.  
9.6. Concomitant Medications 
At each study visit, the investigator will document any medications the subject has taken since 
the pr
eceding visit. All medications taken by the subject beginning at enrollment until the end of 
Day 28 will be recorded.  
9.7. Procedures for Monitoring Subject Compliance 
The malaria challenge will be administered under direct supervision of investigational staff; 
ther
efore, no procedures for monitoring subject compliance are necessary. Subjects will receive 
telephone (verbal or text) reminders prior to their scheduled appointments and subjects will be 
contacted to schedule make-up visits for missed appointments. 
10. SAFETY ASSESSMENT 
Safety monitoring will be conducted throughout the study; therefore safety concerns will be 
identified by continuous review of the data by the PI, clinic staff, clinical monitor, research 
monitor, and United States Army Medical Research and Materiel Command (USAMRMC) 
Office of Regulated Activities (ORA) Product Safety Surveillance Branch (PSSB).   
Study Safety Management:  The IRB, research monitor, and principal investigator will review 
a
ny safety concern. A data safety monitoring board (DSMB) is not required for this study.  
Rese
arch Monitor: The Department of Defense research monitor is responsible for overseeing 
the safe
ty of the research and report observations/findings to the IRB or a designated institutional 
official. The research monitor will review all unanticipated problems involving risks to subjects 
or others associated with the protocol and provide an independent report of the event to the IRB. 
The research monitor may discuss the research protocol with the investigators; shall have 
authority to stop a research protocol in progress, remove individual human subjects from a 
research protocol, and take whatever steps are necessary to protect the safety and well-being of 
human subjects until the IRB can assess the monitor’s report; and shall have the responsibility to 
promptly report their observations and findings to the IRB or other designated official and the 
HRPO. 
In addition to the responsibilities above the research monitor is required to review and provide an 
unbiased written report for all SAEs and subject deaths to the ORA PSSB (Safety Office) within 
24 hour
s of their awareness of the event using the Research Monitor Report form. The report 
provided must include, at a minimum, a brief summary of the research monitor's review of the 
event and event outcome, relationship of the event to the investigational product and whether or 
not the research monitor concurs with the details of the study investigator's report. For this 
protoc
ol the secondary research monitor will provide input in the event of a discrepancy between 
the investigator’s report and the primary research monitor’s report.  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 42  US Government Proprietary The ORA Safety Pharmacovigilance (PVG) physician, as delegated by the sponsor, evaluates all 
safety cases and provides the final determination on relatedness to the product, and whether 
expedited reporting is warranted, per current FDA regulation and guidance. 
USARMRC ORA PSSB:  PSSB  is responsible for coordinating and integrating the review of 
safety data regarding The Surgeon General (TSG)-sponsored products. The PSSB  reviews each 
S
AE report for medical consistency, accuracy, and completeness and follows each event until it 
is satisfactorily resolved. 
10.1. Adverse Event Definitions 
The following terms, as defined by 21 CFR 312.32, apply to IND safety reporting. 
10.1.1. Adverse Event or Suspected Adverse Reaction 
Adve
rse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. 
S
uspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, “reasonable 
possibility” means there is evidence to suggest a causal relationship between the drug and the 
adverse event. Suspected adverse reaction implies a lesser degree of certainty about causality 
than adverse reaction, which means any adverse event caused by a drug. 
10.1.2. Solicited Adverse Event 
For this study, a solicited AE is an event expected as part of malaria infection. The solicited AEs 
for
 this study include: 
 P ruritus at the challenge site  
 Ta chycardia 
 F ever (oral temperature ≥100.4°F/38°C) 
 F everishness (subjective) 
 He adache 
 Fatigue 
 Malaise 
 C hi lls 
 Sweats 
 Arthralgia 
 Myalgia  
 Gastrointestinal symptoms (nausea/vomiting/diarrhea/abdominal pain) 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 43  US Government Proprietary 10.1.3. Serious Adverse Event or Serious Suspected Adverse Reaction 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the inve
stigator or sponsor, it results in any of the following outcomes:  
 De ath 
 L ife-threatening adverse event: an adverse event or suspected adverse reaction is 
considered "life-threatening" if, in the view of either the investigator or sponsor, its 
occurrence places the patient or subject at immediate risk of death. It does not include 
an adverse event or suspected adverse reaction that, had it occurred in a more severe 
form, might have caused death. 
 I npatient hospitalization or prolongation of existing hospitalization 
 P ersistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 C ongenital anomaly/birth defect 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, 
or c
onvulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
10.1.4. Unexpected Adverse Event or Unexpected Suspected Adverse Reaction 
An adverse event or suspected adverse reaction is considered “unexpected” if it is not consistent 
with malaria infection. 
10.1.5.
 Unanticipated Problems Involving Risks To Subjects Or Others 
Federal regulations require that unanticipated problems involving risks to subjects or others be 
promptly reported to the IRB. These events encompass a broader category of events than SAEs 
and may include issues such as problems with loss of control of subject data or the 
investigational product; adverse psychological reactions; or breach of confidentiality. Risks to 
others (eg, program personnel) must also be reported. 
Unanticipated problems involving risks to subjects or others are any incident, experience, or 
outcome
 that meets all of the following criteria: 
 Une xpected (in terms of nature, severity, or frequency) given (a) the procedures that 
are described in the protocol, investigators brochure or informed consent document; 
and (b) the characteristics of the subject population; 
 Related or possibly related to a subject’s participation in the study; and 
 S uggests that the study places subjects or others at a greater risk of harm than was 
previously known or recognized. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 44  US Government Proprietary The IRB and/or the ORP will evaluate reports from the PI and research monitor to determine 
whether a given incident, experience or outcome constitutes an unanticipated problem involving 
risk to subjects or others and, in coordination with the sponsor, ensure upward reporting of the 
una
nticipated problems involving risk to subjects or others to the appropriate regulatory offices. 
1
0.2. Adverse Event Relationship to Investigational Product 
The investigator must assign a relationship of each AE to the receipt of the investigational 
product (in this case, malaria challenge). The investigator will use clinical judgment in 
c
onjunction with the assessment of a plausible biologic mechanism, a temporal relationship 
between the onset of the event in relation to receipt of the investigational product, and 
identification of possible alternate etiologies including underlying disease, concurrent illness or 
concomitant medications. The guidelines in Ta ble 6 should be used by investigators to assess the 
re
lationship of an AE to study product administration.  Only a physician can make this 
de
termination.  
Table 6: Adverse Event Relationship to the Investigational Product Categories 
Relationship  Description  
Not related  No reasonable causal relationship between the investigational product 
administered and the SAE.  Applies to those events for which evidence exists that 
there is an alternate etiology.  
Unlikely  Likely unrelated to the investigational product. Likely to be related to factors other 
than investigational product, but cannot be ruled out with certainty.  
Possibl y An association between the event and the administration of investigational product 
cannot be ruled out. There is a reasonable temporal association, but there may also 
be an alternative etiology such as the subject’s clinical status or underlying factors 
including other therapy.  
Probabl y  There is a high degree of certainty that a relationship to the investigational product 
exists. There is a reasonable temporal association, and the event cannot be 
explained by known characteristics of the subject’s clinical state or factors 
including other therapy.  
Definite  An association exists between the receipt of investigationa l product and the event. 
An association to other factors has been ruled out.  
 
10.3. Adverse Event Severity Assessment 
All AEs will be assessed for severity by the investigator. Inherent in this assessment is the 
medical and clinical consideration of all information surrounding the event including any 
medical intervention required. Each event will be assigned one of the following categories: mild, 
moderate, severe, potentially life-threatening or fatal. Refer to the grading scale in Appe ndix D 
for further guidance in the assignment of severity. The criteria in Table 7 may be used for any 
s
ymptom not included in the grading scale. Any Grade 4 (life-threatening) or Grade 5 (fatal) AE 
must be reported as an SAE. 
The CRF for AEs will reflect only the highest severity for continuous days an event occurred. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 45  US Government Proprietary Table 7: Adverse Event Severity Grading Scale 
Severity  Grade  Description  
Mild 1 Does not interfere with routine activities  
Minimal level of discomfort  
Moderate  2 Interferes with routine activities  
Moderate level of discomfort  
Severe  3 Unable to perform routine activities  
Significant level of discomfort  
Potentially life-threatening  4 Hospitalization , ER, or urgent intervention indicated   
Fatal  5 Results in death  
FDA guidelines for toxicity will be followed; however, if a subject is evaluated in an emergency 
room for nonlife threatening illness or symptoms (ie, visits emergency department on weekend 
for mild problems because the physician’s office is closed), the information from that visit will 
be reviewed and severity of the adverse event will be assessed according to the subject’s clinical 
signs and symptoms. 
As defined by the ICH guideline for GCP, the term “severe” is often used to describe intensity 
(severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event 
itself however, may be of relatively minor medical significance (such as severe headache). This 
is not
 the same as “serious”, which is based on subject/event outcome or action  criteria usually 
a
ssociated with events that pose a threat to a subject’s life or functioning. Seriousness (not 
severity) serves as a guide for defining regulatory reporting obligations.  
1
0.4. Recording Adverse Events 
10.4.1. Methods/Timing for Assessing, Recording, and Analyzing Safety Endpoints 
AEs and SAEs will be assessed at all study visits, documented in the source records, and 
re
corded on the CRFs using accepted medical terms and/or the diagnoses that accurately 
characterize the event. It should be noted that the form for collection of SAE information is not 
the same as the AE CRF. Where the same data are collected, the forms must be completed in a 
consistent manner. The same AE terms, for example, should be used on both forms. When a 
diagnosis is known, the AE term recorded on the CRF will be the diagnosis rather than a 
constellation of symptoms. The investigator will assess all AEs for seriousness, relationship to 
investigational product, severity, and other possible etiologies and record the following on the 
AE CRF: a description of the event ( if the event consists of a cluster of signs and symptoms, a 
diagnosis should be recorded rather than each sign and symptom); onset date and time; stop date 
and time; intensity (recorded as mild, moderate, or severe, potentially life threatening, or fatal); 
seriousness (an SAE Report Form must also be completed for SAEs); causality (relationship to 
study drug); outcome (eg, not recovered/not resolved (ongoing), recovering/resolving, 
recovered/resolved, recovered/resolved with sequelae, death, or unknown (if applicable); and 
action taken with the study agent (eg, no action, study agent discontinued, or other action taken. 
W
hen an event has not resolved by study closure, it will be documented on the AE CRF as 
“ongoing”. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 46  US Government Proprietary The timeframe for the collection of AEs and SAEs begins on the day of the challenge through 
28 days post challenge. 
10.4.2.
 Duration of Follow-Up of Subjects after Adverse Events 
Investigators will follow AEs until resolution or to the end of the study (if not previously 
re
solved), and SAEs to resolution, even if this extends beyond the prescribed reporting period. 
Re
solution is the return to baseline status or stabilization of the condition with the probability 
that it
 will become chronic. The SAE outcomes will be reported to the sponsor’s representative 
using
 the Serious Adverse Event Report Form the USAMRMC Office of Regulated Activities, 
P
roduct Safety Surveillance Branch, SAE mailbox: usarmy.detrick.medcom-usamrmc.mbx.sae-
reporting@mail.mil using the Serious Adverse Event Report Form. 
I
nvestigators are not obligated to actively seek SAEs in former subjects; however, if a SAE, 
considered to be related to the investigational product is brought to the attention of the 
investigator at any time  following completion of the study, the event will be reported to the 
sponsor’
s safety office as defined in Section 10.5 .  
10.5. Reporting Adverse Events 
The PI will report all AEs to the USAMRMC, and the IRB of record in the appropriate safety, 
annual, and/or final reports. After appropriate data cleaning and query resolution between the 
c
linical site, sponsor’s clinical monitor, and clinical data manager, SAEs from the clinical 
database will be reconciled with the sponsor’s SAE database 
10.5.1. Reporting Serious and Unexpected Adverse Events 
Contact information for reporting SAEs is provided in Table 8. 
10.5.1.1.
 Reporting to the Sponsor 
All SAEs must, at a minimum, be reported by emailing or faxing the initial SAE Report Form 
promptl
y (within 24 hours) to the sponsor’s safety office, the Office of Regulated Activities, 
P
roduct Safety Surveillance Branch as per 21 CFR 312.64, whether or not the event is 
c
onsidered related to study product. Further, the investigator should comply with relevant study 
sit
e SOPs on reporting SAEs. 
The minimum information that the investigator will provide to the USAMRMC PSSB is 
spe
cified in Table 9. The sponsor’s representative may request additional information for 
purpo
ses of the study. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 47  US Government Proprietary Table 8: Study Contacts for Reporting Serious Adverse Events and Unanticipated 
P
roblems Involving Risk to Patients or Others 
Sponsor’s Safet y Office  US Army Medical Research & Materiel Command  
ATTN: MCMR -UMR 
1430 Veterans Drive  
Fort Detrick, MD 21702 -5009  
Fax: 301-619-7790  
Telephone:  301-619-1005  
Email:  usarmy.detrick.medcom -usamrmc.mbx.sae -
reporting@mail.mil  
Institutional Review Board  WRAIR IRB 
503 Robert Grant Avenue  
Silver Spring, MD 20910  
Telephone: (301) 319 -9940  
Fax: (301) 319 -9961  
Email: usarmy.detrick.medcom -wrair.mbx.hspb@mail.mil  
USAMRMC Office of Research 
Protections  Human Research Protection Office  
US Army Medical Research and Ma teriel Command  
ATTN: MCMR -RPH  
504 Scott Street  
Fort Detrick, MD 21702 -5012  
Fax: 301 -619-7803  
Telephone: 301 -619-2165  
Email: usarmy.detrick.medcom -usamrmc.other.hrpo@mail.mil  
Research  Monitor s Ramiro Gutierrez , MD , CAPT, MC, USN  
NMRC  
503 Robert Grant Avenu e 
Silver Spring, MD 20910  
Tel: 301-319-3193  
Email: Ramiro.l.gutierrez.mil@mail.mil   
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 48  US Government Proprietary Table 9: SAE Information to be Reported to the Sponsor's Safety Office 
Notification Method  Information to be Provided  
Email or Telephone  
(within 24 hours)  IND number, sponsor study number, name of the investigational product, and 
investigator name and contact number  
 Subject identification number  
 SAE term, description, onset date, date(s) of investigational product 
administration, severity, relationship to the investigational product, and 
subject’s current status  
AND   
Email or Fax  Sponsor -approved Serious adverse event report form   
Medical record progress notes including pertinent laboratory/diagnostic test 
results  
NOTE: When submitting SAE reports via email, the subject line of each email notification will read as 
follows:  
SAFETY REPORT – IND # _____, Sponsor Study #_____ , Subject# _____, Event term: _____  
In order to comply with regulations mandating sponsor notification of specified SAEs to the 
FDA within 7 calendar days, investigators must submit additional information as soon as it is 
available. The sponsor’s representative will report unexpected SAEs associated with the use of 
the dr
ug to the FDA as specified at 21 CFR 312.32 (c).  
Investigators must follow all relevant regulatory requirements as well as specific policy 
regarding the timely reporting of SAEs to the research monitor and the IRB and/or the 
USAMR
MC ORP.  
R
eporting to the sponsor’s safety office does not fulfill the investigator’s duty to report all 
una
nticipated problems involving risk to human subjects or others to the IRB. The PI will notify 
the 
IRB and/or the USAMRMC ORP, and the research monitor.  
10.5.1.2.
 Reporting to the IRB 
Unanticipated problems involving risk to subjects or others, SAEs related to participation in the 
study, and all subject deaths related to participation in the study should be promptly reported by 
tele
phone, email, or fax to the IRB and/or the USAMRMC ORP. A complete written report 
should follow the initial notification. 
Investigators are required to forward safety information provided by the sponsor’s representative 
to the IRB. 
10.5.2.
 Reporting Additional Immediately Reportable Events to the Sponsor’ s Safety 
Office, the IRB, and/or the USAMRMC ORP 
10.5.2.1.
 Pregnancy 
Each pregnancy must be reported immediately (within 24 hours of identification) by completing 
a
nd submitting the Pregnancy Report Form by email or fax to the sponsor’s safety office 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 49  US Government Proprietary (USAMRMC Product Safety Surveillance Branch). Report the incident to local IRB and/or the 
USAMR
MC ORP in accordance with IRB policy. 
Subjects who become pregnant after Day 0 will be followed to term, and the following 
information will be gathered and documented on the Pregnancy Report Form:, for outcome, type, 
da
te of delivery, Apgar scores, and health status of the mother and child including the child’s 
g
ender, head circumference, gestational age at delivery, height, and weight. Complications and 
or a
bnormalities should be reported including any premature terminations. A pregnancy is 
re
ported as an AE or SAE only when there is suspicion that the investigational product may have 
interfered with the effectiveness of contraception or there was a serious complication in the 
pregnancy including a spontaneous abortion or an elective termination for medical rationale. Any 
subject determined to be pregnant after malaria challenge, but before diagnosis and/or treatment 
for malaria, will be treated empirically for malaria using a protocol antimalarial that is safe for 
use in pregnancy. 
10.5.2.2. AE-related Withdrawal of Consent 
Any AE-related withdrawal of consent during the study must be reported immediately (within 
24 hours of identification) by email or fax to the sponsor’s representative. Report the withdrawal 
to l
ocal IRB and/or the USAMRMC ORP in accordance with IRB policy. 
10.5.2.3. Pending Inspections/Issuance of Reports 
The knowledge of any pending compliance inspection/visit by the FDA, Office for Human 
Research Protections (Department of Health and Human Services), or other government agency 
concerning clinical investigation or research, the issuance of Inspection Reports, FDA Form 483, 
warning letters, or actions taken by any regulatory agency including legal or medical actions and 
a
ny instances of serious or continuing noncompliance with the regulations or requirements will 
be reported immediately to the local IRB and/or the USAMRMC ORP and the sponsor’s 
re
presentative (USAMRMC ORA). 
10.5.3.
 Annual and Final Reports 
SAEs and AEs for inclusion in annual and final reports to the FDA will be provided from the 
clinical database by the clinical data manager in USAMRMC ORA. 
10.5.4. IND Annual Report to the FDA 
The PI will be responsible for the preparation of a detailed annual synopsis of clinical activity, 
including adverse events, for submission to the sponsor’s representative (USAMRMC ORA ). 
Each annual report will summarize IND activity for 1 year beginning approximately 3 months 
be
fore the IND FDA anniversary date. The sponsor’s representative will notify the PI of the due 
da
te with sufficient time for the PI to assemble the required information.  
10.5.5.
 Final Report 
A final study report will be prepared in accordance with “Guidance for Industry: Submission of 
Abbr
eviated Reports and Synopses in Support of Marketing Applications”, ICH E3 Guideline 
“Structure and Content of Clinical Study Reports”, and electronic Common Technical Document 
requirements and standards and provided to the sponsor’s representative for review and approval. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 50  US Government Proprietary The sponsor’s representative will use this report to prepare the final clinical study report for 
submission to the FDA.  
11. STATISTICS 
11.1. Description of Statistical Methods 
All data will be collected and verified prior to analysis. No interim analyses are planned. The 
statistical analyses for the trial objectives will be executed as outlined below, unless modified via 
a
 protocol amendment or justified in the final report, as applicable. 
A formal statistical analysis plan (SAP), as a separate document, will contain detailed 
infor
mation regarding data analyses to be performed and will be finalized before database lock or 
da
ta analysis occurs. 
11.1.1. Analysis Addressing the Primary Study Objective 
The primary objective of this trial is to evaluate the infective efficacy of the new lot of NF54 
(clone 3D7) parasites within the standard WRAIR CHMI model.  
This t
rial will evaluate the primary objective by informally comparing the efficacy of the new 
lot, defined as the proportion of subjects with parasitemia confirmed by blood smear, to the 
proportion of historically positive controls from previous studies. Since 2012 (the time of the last 
significant update to challenge procedures) infectivity control subjects in WRAIR CHMI trials 
have demonstrated an overall efficacy of 95.1% (range 83.3-100%), as can be calculated from 
Table 2 in this protocol. A meta-analysis using a mixed model with random intercepts and study 
e
ffects provides a 95% confidence interval of the mean to be 90.1% to 97.6%. 
No f
ormal hypothesis testing of the primary objective will be conducted as the sample size 
needed to conduct a true non-inferiority study is far too great. Following FDA guidance on non-
infe
riority trials, a trial of 220 subjects would be required to detect a difference with the same 
mea
n efficacy (95.1%), 80% power, a one-sided alpha of 0.025, and a non-inferiority margin set 
a
t the 95% lower bound of the historic data (90.1%). This sample size could be reduced to 
36 subjects if the efficacy of the new lot is 100%, of which there is no empirical evidence 
(c
alculated using PASS 16). Such a trial size would represent one of the largest CHMI trials ever 
pe
rformed, and be logistically and financially untenable under current resources. In addition, 
there are potential safety and ethical concerns with exposing such a large number of persons to a 
potentially fatal disease using an untested lot of parasites, whose characteristics, though unlikely, 
may prove different (ie, less safe) than the old lot. 
Every CHMI at WRAIR since 2012 has utilized 6 infectivity control subjects per challenge day. 
In all of these trials, at least 5 of the 6 control subjects developed malaria. If the new lot’s initial 
infective efficacy is lower than the minimum historical infective efficacy of the old lot (5/6, 
83.3%), then the new lot will be considered insufficiently infective, and not be used for further 
human trials without revision, replacement, and/or further bridging trials. However, if the 
infective efficacy meets the minimum historical level (at least 10 of the 12 subjects are positive), 
then the new lot will be considered acceptable for possible use in trials with experimental 
produ
ct. If efficacy is acceptable, it is intended that these 12 subjects will provide the nucleus of 
a new lot data set that will eventually grow large enough, with the addition of control data from 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 51  US Government Proprietary future studies, to perform a true non-inferiority analysis using standardized meta-analysis 
techniques to compare the two lots. 
11.1.2. Analysis Addressing the Secondary Study Objective 
11.1.2.1. Time to Parasitemia  
Time to parasitemia will be determined for all subjects for both smear and qPCR. Time to 
parasitemia will be defined as the time (in Days) from malaria challenge to confirmed 
parasitemia. Confirmed parasitemia by malaria smear will be defined as the observation of 
2 confirmed parasites on a single smear. Confirmed parasitemia by qPCR will be defined as a 
sing
le positive qPCR assay result.  
Time to parasitemia for individual subjects, the median and range time- to-parasitemia, and 95% 
confidence intervals using a t distribution for each diagnostic method will be determined.  
11.1.2.2.
 Time to Clearance  
Time to C
learance will be determined for all subjects for both smear and qPCR. Time to 
Clearance will be defined as the time (in Days) from malaria diagnosis to confirmed clearance of 
parasitemia. Confirmed clearance of parasitemia by malaria smear will be defined as the 
observation of 3 sequential negative (no parasites observed) daily smears. Confirmed clearance 
of parasitemia by qPCR will be defined as 2 sequential daily (approximately 24 hours apart) 
negative qPCR assay results. For clarity, the day of the final test in each sequence (smear, PCR) 
will be used as the day of confirmed clearance for calculation purposes (ie, the clearance will not 
be ‘backdated’ to the first negative result). 
Time to clearance for individual subjects, the median and range time -to-clearance, and 
95% confidence intervals using a t distribution for each diagnostic method will be determined. 
11.1.3.
 Safety Analysis 
Safety analysis will include data collected from all subjects.  Adverse event data will be listed 
individually (including intervention and outcome) and summarized. Serious and/or unexpected 
AE
s will also be discussed on a case- by-case basis. The frequency of each adverse event type 
will
 be presented along with a 95% confidence interval using an exact method for binomial 
distributions. 
11.2. Planned Enrollment and Reason for Sample Size 
A maximum of 12 subjects will be enrolled in this study, defined as receiving malaria challenge. 
This trial is not designed or powered to conduct formal hypothesis testing, but will provide basic 
descriptive statistics on the infective efficacy of the new malaria lot. A sample size of 12 subjects 
will provide a start to a formal non-inferiority meta-analysis, while providing preliminary 
efficacy results to either justify future trials with the new lot or rejection of the new lot. 
Additi
onally, in choosing the number of subjects for this trial, the team had to balance the risk to 
volunteers (from exposure to a potentially life-threatening illness) against the benefits of 
challenging additional subjects to provide a more significant proof of infectivity. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 52  US Government Proprietary If it is assumed that the new lot will have the same efficacy as the old lot (95.1%), we can 
construct a binomial distribution to calculate the probability of how many failures (subjects that 
do not become positive) we expect to see in this trial. For comparison, the same distribution was 
c
onstructed using the probability of the 95% lower bound of the historic mean. Additionally, 
Ta
ble 10 displays the infective efficacy rates and the associated 95% confidence intervals. 
T
able 10: Cumulative Probability of Experiencing Failure and Efficacy Rates 
Number of Fai lures  Probability  of 
success is 95.1%  
(n=12)  Probability  of 
Success is 90.1%  
(n=12)  Efficacy Rate and 95% 
Confidence Interval  
(n=12)  
No failures  54.7%  28.6%  100% ( 73.5% – 100%)  
No more than 1 failure  88.6%  66.4%  91.7% (61.5% - 99.8%)  
No more than 2 failures  98.1%  89.2%  83.3% (51.6% - 97.9%)  
No more than 3 failures  Fails efficacy test  Fails efficacy test  75.0% (42.8% - 94.5%)  
 
From Table 10 , there is a probability of 98.1% that there will be no more than 2 failures when 
a
ssuming that the efficacy is the same as the old lot. This same success probability drops to 
89.2% if we assuming an efficacy rate of 90.1%, the lower bound of the 95% confidence 
interval. 
Table 11 displays the width of the confidence intervals for adverse events using an exact 
binom
ial calculation. 
Table 11: Width of Confidence Intervals for Frequency of Adverse Events 
Number of Events  Probability  95% Confidence 
Interval  
1 event  8.3%  0.2% - 38.5%  
2 events  16.7%  2.1% - 48.4%  
3 events  25.0%  5.5% - 57.2%  
6 events  50.0%  21.1% - 78.9%  
12 events  100%  73.5% - 100%  
In consideration of all these factors, the team has concluded that 12 subjects (at least 6 per 
c
hallenge day) is  the appropriate sample size for this study.  
11.3. Level of Significance to be Used 
No formal statistical testing is planned in this analysis. Confidence intervals will be presented 
when appropriate and will use a 95% confidence interval.  
11.4. Statistical Criteria for the Termination of the Trial 
There are no statistical criteria for study termination in this trial. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 53  US Government Proprietary 11.5. Accounting for Missing, Unused, and Spurious Data 
The SAP will be followed even if data are missing. Subjects with missing data will not be 
replaced nor will missing values within any subject’s record be imputed. Non analyzable data 
will be documented in the deviations. 
11.6. Procedures for Reporting Deviations from the Original Statistical 
Plan 
Any deviation(s) from the original SAP as indicated in the protocol will be described in an 
amendment to the protocol and the SAP. Deviations from the SAP will be documented in 
accordance with study site SOPs. 
11.7. Selection of Subjects to be Included in Analyses 
For analysis of the primary objective, as well as for the secondary objectives regarding time to 
parasitemia and clearance of parasitemia, data from all subjects who are challenged will be 
included. 
12. ADMINISTRATIVE 
12.1. Ethics 
12.1.1. Ethics Review/Institutional Review Board 
This study will be conducted in accordance with all applicable Federal and DoD human research 
protections requirements and the Belmont Principles of respect for persons, beneficence, and 
just
ice.  
The procedures set out in this study are designed to ensure that the sponsor’s representative and 
all study personnel abide by the principles of the ICH GCP Guideline and the CFR. The PI 
confirms this by signing this study protocol and FDA Form 1572. 
The study will be conducted under a protocol reviewed by the IRB of record. The study is to be 
conducted by scientifically and medically qualified persons. The IRB will determine whether the 
benefits of the study are in proportion to the risks. The rights and welfare of the subjects will be 
respected; the physicians conducting the study will ensure that the hazards do not outweigh the 
potential benefits; the results to be reported will be accurate; subjects will give their informed 
consent and will be competent to do so and not under duress; and all study staff will comply with 
the ethical principles in 21 CFR Part 50 and the Belmont Principles. 
Enrollment in this protocol will not begin until all required approvals have been obtained and the 
formal authorization letter is received by the PI from the sponsor’s representative. 
12.1.2. Confidentiality 
In this research, the subject’s health information will be collected and used to conduct the study; 
to m
onitor the subject’s health status; to measure effects of the malaria challenge; to determine 
research results, and possibly to develop new tests, procedures, and commercial products. Health 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 54  US Government Proprietary information is used to report results of research to the sponsor’s representative and Federal 
regulators and may be reviewed during study audits for compliance with study plans, regulations, 
and research policies. After the study ends, each subject has the right to see and receive a copy of 
his/
her information. 
Representatives of the TSG as the IND sponsor, USAMRMC ORA as the sponsor’s 
representative, the local IRB and/or the ORP, the DoD, and the FDA are eligible to photocopy 
and review records related to this protocol as a part of their responsibility to protect the 
participants of this protocol. In addition, these representatives are eligible to witness the 
applicable study procedures to assure the safety of subjects. 
No personal identifier will be used in any publication or communication used to support this 
research study. The subject’s identification number will be used in the event it becomes 
ne
cessary to identify data specific to a single subject. 
Although every measure will be taken to assure the confidentiality of subjects in this study, there 
is the theoretical risk associated with breach of confidentiality by participating in this study. In a 
few select circumstances, complete confidentiality will be unable to be guaranteed for subjects. 
These will include required reporting of transfusion-transmissible infectious diseases (such as 
HIV or hepatitis) to applicable military and public health agencies, and required reporting of 
criminal offenses under the Uniform Code of Military Justice (UCMJ) to appropriate military 
authorities. All subjects will be informed of these exceptions to confidentiality during the 
c
onsent process. 
12.1.3.
 Compensation for Participation 
A subject will be compensated for the time and effort required for his or her participation in this 
study and for specific study procedures (such as blood collection). A breakdown of specific 
compensation for each visit is provided in the consent documentation. 
Compensation for screening will be $50 for all potential subjects, regardless of whether that 
potential subject is eligible for or interested in enrollment in the study. Compensation for each 
study visit will range from $50 to $350 (including bonus) for civilian subjects who are not 
Federal employees. For subjects who are Federally employed (military or civilian), 
compensation is limited to $50 per visit and can only be given for visits in which blood is drawn, 
unless the subject is on approved leave, or the visit occurs outside of normal duty hours. In these 
c
ases, Federally-employed subjects will be eligible for the same compensation as civilian 
subjects who are not Federal employees. 
For unscheduled visits which involve a laboratory draw, subjects will be compensated $50. 
Assuming no unplanned visits, civilian (non-Federal employee) subjects who participate will be 
receive up to approximately $2875 in compensation. Federally-employed subjects who 
participate will receive up to approximately $1250 in compensation, unless they are on approved 
lea
ve or participating outside of normal duty hours. 
Subjects who choose to stop participation in the study will retain all of the compensation to 
which they are entitled up to the time they leave the study. Subjects who are removed from the 
study by the investigator for failure to comply with study procedures will retain all of the 
compensation to which they were entitled up to the time of the action. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 55  US Government Proprietary Subjects will not be compensated for travel expenses incurred as a result of their participation in 
this study nor will transportation be provided for them. 
Compensation payments will be distributed after completion of the pertinent study visit or phase. 
Payment will be by cash, check, or pre-paid debit/ATM card or by direct deposit. Payment will 
generally either be provided by direct hand- to-hand distribution to the subject, or through 
electronic allotment to a previously distributed pre-paid debit/ATM card. However, in rare cases 
checks may be mailed to subjects. Payments for several visits may be bundled for efficiency and 
convenience of study staff. Subjects will be informed in the consent process that if they receive 
more than $600 for their participation in the study, study personnel will be required to report 
subject compensation as income to the IRS via a Form 1099. 
The payments described above are the only financial compensation available to subjects for their 
participation in this research. 
12.1.4. Medical Care for Research-Related Injury 
All non
-exempt research involving human subjects shall, at a minimum, meet the requirement of 
32 CFR 219.116(a)(6). 
If a subject is injured because of participation in this research and is a DoD healthcare 
beneficiary (eg, active duty in the military, military spouse or dependent), the subject is entitled 
to medical care for that injury within the DoD healthcare system, as long as the subject remains a 
DoD healthcare beneficiary. This care includes, but is not limited to, free medical care at Army 
hospi
tals or clinics. 
If a subject is injured because of participation in this research and is not a DoD healthcare 
be
neficiary, the subject entitled to medical care for that injury at an Army hospital or clinic; 
medical care charges for care at an Army hospital or clinic will be waived. The subject is also 
entitled to care for that injury, but such care for that injury at other DoD (non-Army) hospitals or 
clinics may be limited by time, and the subject’s insurance may be billed. It cannot be 
determined in advance which Army or DoD hospital or clinic will provide care. If the subject 
obtains care for research-related injuries outside of an Army or DoD hospital or clinic, the 
subj
ect or the subject’s insurance will be responsible for medical expenses.  
12.1.5.
 Written Informed Consent 
The informed consent process and document will be reviewed and approved by the local IRB 
and/or the ORP and sponsor’s representative prior to initiation of the study. The consent 
doc
ument contains a full explanation of the possible risks, advantages, and alternate treatment 
options, and availability of treatment in the case of injury, in accordance with 21 CFR 50. The 
c
onsent document indicates that by signature, the subject permits witnessing of applicable study 
proc
edures by the sponsor’s representative, as well as access to relevant medical records by the 
sponsor’
s representative and by representatives of the FDA. The sponsor’s representative wi ll 
submit a copy of the initial IRB- and sponsor’s representative-approved consent form to the FDA 
and will maintain copies of revised consent documents that have been reviewed and approved by 
the local IRB and/or the ORP.  
A written informed consent document will be signed by the subject before any study-related 
proc
edures are initiated for that subject. This consent document must be retained by the 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 56  US Government Proprietary investigator as part of the study records. Each subject will receive a copy of the signed informed 
consent document. The investigators or their designees will present the protocol in lay terms to 
indi
vidual subjects. Questions on the purpose of the protocol, protocol procedures, and risks to 
the subjects will then be solicited. Any question that cannot be answered will be referred to the 
P
I. No subject should grant consent until questions have been answered to his/her satisfaction. 
The subject should understand that the study product is an investigational drug and is not 
li
censed by the FDA for commercial use, but is permitted to be used in this clinical research. 
I
nformed consent includes the principle that it is critical the subject be informed about the 
principal potential risks and benefits. This information will allow the subject to make a personal 
risk versus
 benefit decision and understand the following:  
 P articipation is entirely voluntary,  
 S ubjects may withdraw from participation at any time, 
 R efusal to participate involves no penalty, and  
 The  individual is free to ask any questions that will allow him/her to understand the 
nature of the protocol. 
Should the protocol be modified, the subject consent document must be revised to reflect the 
changes to the protocol. If a previously enrolled subject is directly affected by the change, the 
subject will receive a copy of the revised informed consent document. The approved revision 
will be read, signed, and dated by the subject. 
The subject will be informed that a description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by US law.  
12.2. Protocol Approval and Modification 
12.2.1. Review/Approval of Study Protocol 
Before a clinical study can be initiated, the study protocol and other required documents will be 
submitted to the following departments in the order listed for review and/or approval, with the 
final review by the FDA: 
 I ntegrated Product Team 
 Sponsor’s Representative Team (USAMRMC ORA) 
 Sponsor Protocol Review Board 
 L ocal IRB and/or the ORP 
 Sponsor’s Representative (acting for The Surgeon General of the Army) 
Enrollment in this protocol will not begin until all approvals have been obtained and the formal 
authorization letter is received by the PI from the sponsor’s representative. 
12.2.2. Protocol Modifications 
All modifications to the protocol and supporting documents (informed consent, study-specific 
proc
edures, SOPs, recruitment materials, etc) will be reviewed and approved prior to 
implementation. Any protocol amendment will be agreed upon and approved by the sponsor’s 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 57  US Government Proprietary representative prior to submission to the local IRB and/or the ORP and prior to implementation 
of said change or modification. Any modification that could potentially increase risk to patients 
will be submitted to the FDA prior to implementation.  
The informed consent document will be revised to concur with any amendment as appropriate 
a
nd must be reviewed and approved with the amendment. Any subject already enrolled in the 
progr
am will be informed of the revision and asked to sign the revised informed consent 
doc
ument if the modification directly affects the individual’s participation in the program. A 
cop
y of the revised, signed, and dated informed consent document will be given to the patient. 
All orig
inal versions of the informed consent document will be retained in the protocol 
regulatory file, and a copy will be retained in the protocol regulatory file. 
12.2.3. Protocol Deviation Procedures 
All subject-specific deviations from the protocol (eg, failure to return for follow-up visits or 
blood collection within the time indicated in the protocol) will be documented. The PI or 
designee will be responsible for identifying and reporting all deviations, which are defined as 
isol
ated occurrences involving a procedure that did not follow the study protocol or study-
spe
cific procedure. Deviations will be reported annually in the continuing review report to the 
loca
l IRB and/or the ORP and, if appropriate, in the final study report. Action taken in response 
to t
he deviation, and the impact of the deviation will be assessed by the PI or subinvestigator and 
recorded as significant or nonsignificant. 
Significant or major deviations are departures from protocol that have a potential to affect the 
rights of the research participant, to increase the risk to the participant, to change the willingness 
of the subject to continue participation, or to compromise the integrity of the study data in such a 
way
 that the study objectives may not be achieved. Major deviations that occur in greater than 
minimal risk protocols will be reported to the IRB of record within 48 hours of identification and 
recorded in the deviation study log, and a written report submitted within 10 working days of 
be
coming aware of the deviation. All reports will be submitted with a cover memo naming the 
protocol, description of the event, summary of any harm to study participant(s) and steps to 
prevent further deviations. A summary of the major deviations occurring within the reporting 
period should also be included in the continuing review reports . 
I
nsignificant or minor deviations are routine departures that typically involve a subject’s failure 
to compl
y with the protocol (Example: missing scheduled visits). Minor deviations that occur in 
greater than minimal risk protocols will be reported to the IRB of record in the Continuing 
Review Report(s) or Closeout Report.  
Any protocol deviation that adversely affects the safety or rights of a subject or scientific 
integrity of the study or any instances of serious or continuing non-compliance with the 
regulations or requirements will be reported immediately to the sponsor’s representative (through 
USAMRMC ORA), the local IRB, and/or the ORP. 
12.3. Sample and Data Handling  
The primary source document for this study will be the subject's medical record. If separate 
research records are maintained by the investigator(s), the medical record and the research 
re
cords will be considered the source documents for the purposes of auditing the study. All 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 58  US Government Proprietary source documents and subject study files will be retained at the site and stored in a locked 
records room with key access only given to WRAIR CTC key personnel. 
F
or this study, an EDC database system will be used for the collection of the study data in an 
electronic format. The EDC database system will be designed based on the protocol 
requirements, the approved eCRF layouts and specifications, and in accordance with 21 CFR 
Part 11. The eCRF layouts and specifications define and identify the applicable source data that 
will be collected and captured into the EDC database system. The applicable source data will be 
electronically entered by the study site designee onto the eCRF (data entry screens) in the EDC 
database system. The investigator is ultimately responsible for the accuracy of the data 
transcribed on the eCRF. Data monitoring and management will be performed in the EDC 
database system by the study clinical monitor and the designated data management group. 
A detailed data management plan will be written and approved by the designated data 
management group and the Sponsor’s oversight data management 
12.3.1. Sample Handling and Management 
Samples collected under this protocol will be used to conduct screening, protocol-related safety 
evaluations and to generate de-identified control pools for malaria-research assays and future 
use. The amounts of blood to be drawn are provided in Table 3 and Table 4 . All samples will be 
c
ollected using standard techniques and safety precautions. To maintain clarity and 
confidentiality, specimens will be labeled with at least the collection date or visit number, study 
number
, and the applicable subject identification (ID) code (either screening or study) for the 
subject. Labels may be in barcode or text format. 
If necessary, biological samples will be stored temporarily at the CTC to await transport to 
appropriate laboratories for processing and analysis. Transport and storage of these biological 
samples will be handled according to applicable SOPs.  
Samples collected for safety assessments will be transported to the applicable local commercial 
laboratory for testing. Storage and destruction of these samples will be as per the applicable 
laboratory SOPs. It is expected that these samples will be destroyed by the testing facility shortly 
after successful completion of testing (as per their SOPs), and no long term storage of these 
samples is planned. 
Samples collected for de-identified control pool generation and future use, will likewise be 
tra
nsported to the Malaria Serology Laboratory and Flow Cytometry Center at WRAIR for 
processing, use, and storage.  
Storage and destruction of these samples will be as per the applicable facility SOPs. These 
samples, either individually, or in pool form, will be stored for a maximum of 20 years (counting 
from when the last subject performed the last study visit), unless local rules, regulations or 
guidelines arise in the interim which require different timeframes or different procedures.  
Any study involving the future use of biological specimens obtained under this study will require 
the appropriate IRB approval. Specimens will not be stored for future use without written 
consent from the study subjects. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 59  US Government Proprietary 12.3.2. Data Management 
The laboratory data will be either be uploaded as a batch file from the laboratories to the study 
database and/ or the site will transcribe the data from the source documents and then enter it into 
a validated, password-protected data management system. Source documents will be stored at the 
clinical site in an access-controlled, locked storage space. 
Subjects will be identified on CRFs by a unique subject identification number and on source 
documents by name and date of birth. No personal identifier will be used in any publication or 
communication used to support this research study. The subject identification number will be 
used if it becomes necessary to identify data specific to a single subject. Representatives of 
USAMRMC, the sponsor’s representative, the local IRB and/or the USAMRMC ORP, and the 
FDA are eligible to review medical and research records related to this study as a part of their 
responsibility to protect human subjects in clinical research. Personal identifiers will be removed 
from photocopied medical and research records. 
12.3.3. Retention of Records 
The PI  must maintain all documentation relating to the study for a period of at least 2 years after 
the c
ompletion of the investigation. If it becomes necessary for the sponsor’s representative or 
desig
nee or the FDA to review any documentation relating to the study, the investigator must 
permit access to such records. 
The PI will be responsible for retaining sufficient information about each subject, so that the 
sponsor’s representative, the local IRB, the FDA, employees of USAMRMC, or other regulatory 
a
uthorities may have access to this information should the need arise.  
It is the policy of the USAMRMC that data sheets are to be completed for all subjects 
participating in research (Form 60-R, Volunteer Registry Data Sheet). The data sheets will be 
entered into this Command’s Volunteer Registry Database. The information to be entered into 
this confidential data base includes the subject’s name, address, and Social Security Number; 
study title; and dates of participation. The intent of this data base is twofold: first, to readily 
a
nswer questions concerning an individual’s participation in research sponsored by USAMRMC; 
and second, to ensure that USAMRMC can exercise its obligation to ensure research subjects are 
adequately warned (duty to warn) of risks and to provide new information as it becomes 
a
vailable. The information will be stored at USAMRMC for a minimum of 75 years. The 
Voluntee
r Registry Database is a separate entity and is not linked to the study database. 
12.4. Study Monitoring 
Study monitoring will be the responsibility of the USAMRMC ORA. Upon successful approval 
of the protocol and establishment of the regulatory file, the clinical monitor will establish a 
clinical monitoring plan. To ensure that the investigator and the study staff understand and 
accept their defined responsibilities, the clinical monitor will maintain regular correspondence 
with the site and may be present during the course of the study to verify the acceptability of the 
facilities, compliance with the investigational plan and relevant regulations, and the maintenance 
of complete records. As needed, the clinical monitor may witness the informed consent process 
or other applicable study procedures to assure the safety of subjects and the investigators’ 
compliance with the protocol and GCPs. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 60  US Government Proprietary Monitoring visits by a sponsor’s representative-designated clinical monitor will be scheduled to 
take place at the initiation of the study, during the study at appropriate intervals, and after the last 
subject has completed the study. A report of monitoring observations will be provided to the PI 
(for c
orrective actions) and the product manager.  
If appropriate, the monitoring plan will be provided to the IRB for review.  
12.5. Audits and Inspections 
Authorized representatives of the sponsor, the FDA, the independent ethics committee or 
institutional review board may visit the site to perform audits or inspections, including source 
data verification. The purpose of the audit or inspection is to systematically and independently 
examine all study-related activities and documents to determine whether these activities were 
conducted, and data were recorded, analyzed, and accurately reported according to the protocol, 
GCP guideline of the ICH, and any applicable regulatory requirements.  
Knowledge of any pending compliance inspections/visits by OHRP, FDA, or other government 
a
gencies concerning clinical investigation or research, the issuance of inspection reports, 
warning letters or actions taken by any regulatory agencies including legal or medical actions 
and any instances of serious or continuing noncompliance with the regulations or requirements 
will be reported immediately to the IRB of record and USAMRMC ORA by phone, email, or by 
facsimile.  
The HSPB will report knowledge of any pending inspections/audits by regulatory agencies to the 
US Army Medical Research and Materiel Command (USAMRMC), Office of Research 
Protections (ORP), Human Research Protection Office (HRPO) as per SOP UWZ-C-636. 
12.6. Access to Source Data/Documents 
The investigators and study staff, the DoD research monitor, members of the IRB of record, 
representatives of the USAMRMC including ORA, DoD, and other government agencies are 
a
uthorized access to the study data as part of their duties and part of their responsibility to protect 
human subjects in research. 
1
2.7. Reports 
12.7.1. Annual and Final Reports 
The principal investigator will report all AEs to USAMRMC and the local IRB in the appropriate 
safety, annual, and/or final reports. After appropriate data cleaning and query resolution between 
the clinical site, sponsor’s clinical monitor, and clinical data manager, SAEs from the clinical 
database will be reconciled with the sponsor’s SAE database. SAEs and AEs for inclusion in 
annual and final reports to the FDA will be provided from the clinical database by the clinical 
data manager in USAMRMC ORA. 
12.7.1.1. IND Annual Report to the FDA 
The PI will be responsible for the preparation of a detailed annual synopsis of clinical activity, 
including adverse events, for submission to the sponsor’s representative (USAMRMC ORA). 
Each annual report will summarize IND activity for 1 year beginning approximately 3 months 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 61  US Government Proprietary before the IND FDA anniversary date. The sponsor’s representative will notify the PI of the due 
date with sufficient time for the PI to assemble the required information.  
12.7.1.2. Final Report 
A final study report will be prepared in accordance with “Guidance for Industry: Submission of 
Abbreviated Reports and Synopses in Support of Marketing Applications”, ICH E3 Guideline 
“Structure and Content of Clinical Study Reports”, and electronic Common Technical Document 
re
quirements and standards and provided to the sponsor’s representative for review and approval. 
The sponsor’s representative will use this report to prepare the final clinical study report for 
submission to the FDA.  
12.7.2. IRB Reports 
12.7.2.1. Continuing Review Reports 
The PI will prepare and submit continuing review reports and comply with other in accordance 
with 
IRB guidance and expectations and will comply with other IRB expectations: 
 S ubmitting the required continuing review reports and associated documents to the 
applicable HSPB, allowing sufficient time for review and continuation determination 
prior to the established continuing review date. 
 R esponding to all requests for information from the IRB of record, and complying 
with any determinations made by the IRB regarding the continuing review. 
 Ensur ing that no human subject research, including data analysis, is conducted on the 
protocol unt
il IRB continuation is granted if the IRB approval lapses without 
continuing review approval. 
 Tracking IRB approvals from the collaborative institutions if the research is 
collaborative in nature to ensure that they are all submitted in a timely manner. 
12.7.2.2.
 Closeout Report 
The PI is responsible for submitting a closeout report and associated documents to the IRB upon 
the completion of the study. 
13. PUBLICATION POLICY 
All data collected during this study will be used to support this IND. All data may be published 
in t
he open medical or military literature with the identity of the subjects protected. Anyone 
de
siring to publish or present data obtained during the conduct of the study will conform to local 
site policies and then forward the publication to USAMRMC ORA prior to submission. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 62  US Government Proprietary 14. LIST OF REFERENCES 
Ballou WR, Sherwood JA, Neva FA, et al. Safety and efficacy of a recombinant DNA 
Plasmodium fal
ciparum  sporozoite vaccine. Lancet 1987;8545:1277-1281. 
Ga
ziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based 
method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. 
The Lancet. 2008;371(9616):923-31.  
Nieman A-E, de Mast Q, Roestenberg M, et al. Cardiac complication after experimental human 
malaria infection: a case report. Malaria Journal. 2009;8(1):277. 
Oc
kenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial 
of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium 
falciparum malaria. J Infect Dis. 1998 Jun; 177(6):1664-73. 
R
ickman LS, Jones TR, Long GW, et al. Plasmodium falciparum -infected Anopheles stephensi  
inconsistently transmit malaria to humans. Am J Trop Med Hyg 1990;43(5):441-445. 
S
ealed Envelope Ltd. 2012. Power calculator for binary outcome non-inferiority trial. [Online] 
Available from: https://www.sealedenvelope.com/power/binary-noninferior/ [Accessed Wed Jan 
02 2019]. 
Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant 
circumsporozoite protein vaccine against Plasmodium falciparum  malaria. RTS,S Malaria 
Va
ccine Evaluation Group. N Engl J Med. 1997 Jan 9;336(2):86-91. 
Tang D. 6 January 1999. Memorandum for Deputy Chief of Staff for Regulatory Compliance 
and Quality, US Army Medical and Material Command entitled “Use of Controls in Protocol 
Log No. A-8567”.  
van Meer MP, Bastiaens GJ, Boulaksil M, et al. Idiopathic acute myocarditis during treatment 
for controlled human malaria infection: a case report. Malar J. 2014;13(1):38. Epub 2014/02/01. 
Verhage DF, Telgt DS, Bousema JT, et al. Clinical outcome of experimental human malaria 
induced by Plasmodium falciparum -infected mosquitoes. The Netherlands journal of medicine. 
2005;63(2):52-8. Epub 2005/03/17. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 63  US Government Proprietary 15. APPENDICES 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 64  US Government Proprietary APPENDIX A. RECRUITMENT SCRIPT 
Study Title:  
“Bridging Trial to Evaluate the Infectivity Equivalence of the Current and New Lots of 
Plasmodium falciparum strain NF54 (clone 3D7) within the WRAIR Controlled Human Malaria 
Infection (CHMI) Model”  
Study Objective:  
This stud
y is being conducted to evaluate the safety and effectiveness of a new lot of malaria 
parasites in causing human infection. 
Study Duration:  
Including the screening period, people who participate in this trial will be in the study for 
approximately 3 months.  
Number of People in the Study:  
12 volunteers12volunteers will be enrolled to undergo the malaria challenge procedure. A few 
other
s may be recruited to serve as alternates in case one of the original 12original12 cannot be 
c
hallenged. 
Study Background:   
Malaria is a parasitic disease transmitted by mosquitoes. It is a significant cause of death and 
disability in tropical areas of Africa, Asia, Oceania (Pacific islands) and Latin America. The U.S. 
military and other groups around the world are working to develop treatments and vaccines 
against this disease. One of the best research tools these groups have to evaluate the effectiveness 
of their potential treatments is called the Controlled Human Malaria Infection (CHMI) model. In 
this model, subjects who have been treated with a drug or vaccine are exposed to malaria 
infection via the bite of laboratory-raised mosquitoes containing malaria parasites. If the drug or 
vaccine works, subjects remain healthy; if not, the subjects become ill with malaria and are 
treated. This model has worked safely and well for over 30 years, with over 1,500 people 
c
hallenged in studies performed by the Department of Defense. Unfortunately, the current supply 
of primary type of parasites used for this challenge model is running out and needs to be 
replaced. A new supply of the parasites has been created, but needs to be tested in a small group 
of subjects to ensure it can cause infection, before it can be used in future drug and vaccine 
studies. That is the purpose of this trial. 
Brief Review of Inclusion / Exclusion Criteria (Full Criteria in Protocol): 
Inclusion: 
 Men and non-pregnant, non-breast-feeding women, civilian or military 
 Ages 18-50 (inclusive) 
 I n good health 
 Able to make all study appointments 
 No plans to travel to a country with malaria throughout the study 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 65  US Government Proprietary Exclusion: 
 History of malaria  
 Hist ory of living for more than 5 years total in an area with malaria  
 Tr avel to a country with malaria in the last 6 months, or planned travel to a country 
with malaria during the study  
 Hist ory of receiving of an investigational malaria vaccine at any time 
 Use  of malaria medications or certain antibiotics within the past 28 days 
 Hist ory of allergy or other severe reaction to either mosquito bites or the malaria 
medications to be used in the trial [atovaquone/proguanil (Malarone), 
artemether/lumefantrine (Coartem), chloroquine] 
 Heart, lung, liver, or kidney disease (high blood pressure, diabetes) 
 Ne urologic disease or chronic migraine headaches 
 S plenectomy 
 Hist ory of sickle cell trait, sickle cell disease, or other blood diseases 
 P ositive for HIV or viral hepatitis 
 Use  of any investigational drug or non-registered vaccine within 30 days before 
challenge 
 Pregnancy or planned pregnancy during the study time period 
 Active duty military volunteers will require approval from their supervisory chain 
 Alc ohol or drug abuse 
 An y other significant finding that in the opinion of the clinical investigators would 
make participation in the study unsafe 
Study Plan: 
Screening 
A person who wants to enroll in the study will be screened to ensure they are eligible to 
participate. 
Screening includes: 
 A detailed explanation of the study 
 Completion of the informed consent documents 
 Brief medical history and physical exam 
 Ur ine and blood tests 
 EK G (electrocardiogram which measures the "electrical activity" of the heart) 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 66  US Government Proprietary Challenge 
 Volunteers will consent to participate in a malaria challenge to find out if the new lot of 
parasites is effective in causing malaria infection. The challenge involves being bitten by 
mosquitoes infected with the malaria parasite. The mosquitoes are contained in a small 
cup with a screen on top. This procedure doesn't hurt, but the volunteer's arm may itch 
later, as with any mosquito bite. Volunteers are expected to develop malaria from the 
mosq
uito bite. 
 A ur ine pregnancy test will be performed for all women before the challenge 
Post-challenge and Hotel Phase: 
 Voluntee rs will need to return to the Clinical Trials Center daily from Days 1-9 after 
the c
hallenge to provide blood for testing. 
 S tarting the night of the 9th (ninth) day after the initiation of malaria challenges, 
volunt
eers will need to check in to a local hotel for a maximum of 10 nights to allow 
for
 rapid assessment and treatment by study staff. The reason is that this is the period 
of time volunteers are most likely to develop malaria. 
 Ea ch morning, volunteers will be seen by a study physician and have a small amount 
of blood drawn to test for malaria. 
 Ea ch afternoon, volunteers will speak with a staff member to get test results and 
report how they feel. 
 Voluntee rs will only have to sleep at the hotel, but can come and go for work and 
outside activities as long as they return for clinical visits. 
 The  symptoms of malaria include fever, chills, headache, fatigue, vomiting, diarrhea, 
muscle aches, and stomachache. 
 I f malaria does develop, volunteers will be treated with a medication taken by mouth. 
All drugs that might be used (chloroquine, Malarone, Coartem) are FDA approved 
and have been used safely for many years. These medications are expected to 
completely cure the malaria. 
 All vol unteers who do not develop malaria by Day 19 after challenge will be treated 
for malaria, regardless of whether they have any evidence of infection. 
Post-Hotel Phase: 
 Voluntee rs who do not complete their malaria treatment in the hotel will be required 
to come to the clinic for one or more days to complete their treatment and to have 
blood testing to confirm they are cured. 
 All vol unteers will have a final visit approximately 1 month after challenge. 
 B lood will be drawn at most of the visits for this trial. 
Risks to the Volunteers may include:  (Note: study staff have methods to decrease or limit 
most
, if not all, side effects) 
 F rom challenge:  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 67  US Government Proprietary  Local reaction at the site where mosquitoes bite 
 Side effects from the FDA approved anti-malaria medications (such as upset 
stomach, nausea, diarrhea, tiredness, ringing in ears) 
 F rom malaria:  
 Fever 
 Chills 
 Headache 
 Fatigue 
 Vomiting 
 Diarrhea 
 Muscle aches 
 Stomach ache 
 F rom blood draws: bruising at the site 
 L oss of confidentiality: For each volunteer that participates in this study, there is a 
chance that limited volunteer information may be disclosed to persons outside of this 
stud
y to include: the USAMRMC, the Food and Drug Administration (FDA), and the 
W
RAIR Institutional Review Board (IRB). These representatives may have access to 
re
view research records as part of their responsibility to protect humans in research 
but they must also maintain confidentiality of volunteer records within the limits of 
the la
w. 
Compensation:  
Volunteers will be financially compensated for their time and effort. 
Study Setting:  
Outpatient 
Closing Remarks: 
If you are interested in learning more about this study or the Clinical Trials Center and what we 
do, please call us using the contact information below and provide the following information to 
the staff: 
 Na me 
 Date of Birth 
 P hone number 
 Email address 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 68  US Government Proprietary Contact Information:WRAIR Clinical Trials  Center  
503 Robert Grant Ave, Silver Spring, MD 20910  
Hours:  Mon-Fri, 6:00am – 2:30pm  
Call
: 1-866- 428-2788 
E
mail: usarmy.detrick.medcom-wrair.mbx.clinical-trials@mail.mil 
Text:  301-215-0388 
E
mail: usarmy.detrick.medcom-wrair.mbx.clinical-trials@mail.mil. We can store your 
information in a database if you wish to be contacted for future studies. 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 69  US Government Proprietary APPENDIX B. INFORMED CONSENT COMPRE HENSION 
ASSESSMENT  
 
Name: _________________________________________________ 
1. Medical screening for this study will include which of the following? 
A. Laboratory tests (including an HIV test) 
B. Physical examination 
C. Review of medical history 
D. All of the above 
 
2. B
y participating in this study, you are expected to develop malaria. 
A. Tr
ue 
B. False 
 
3. The challenge phase of the study involves subjects being bitten by which of the following? 
A. Spiders infected with malaria 
B. Mosquitoes infected with malaria 
C
. Ants infected with malaria  
 
4. What are common findings associated with malaria infection? 
A. Fever 
B. Chills 
C. Headache 
D. All of the above 
E. None of the above 
 
5. If you participate in this study, for how long will you be unable to donate blood? 
A. 3 years 
B. 25 years 
C. Never able to donate blood again 
 
6. If you participate in this study, you may: 
A. Withdraw voluntarily at any time 
B. Never withdraw from the study 
 
 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 70  US Government Proprietary 7. If our specific medical instructions are not followed in this study, malaria infection can cause 
A. D
eath 
B. Serious illness 
C. Multi-organ failure 
D. All of the above 
 
8. Which of the following are true regarding pregnancy and participation in this study? 
A. Pregnant women may participate in this study 
B. Women should not get pregnant for 12 months after getting malaria 
C
. Women in the study must agree to use a form of birth control while participating in this 
study up until the last study visit (3 months after the challenge) 
 
9. Which of the following is a component of this study? 
A. Staying overnight in a hotel each night for up to 10 nights during the challenge phase 
B
. Staying overnight in a hospital for up to 10 nights during the challenge phase 
C
. Coming and going as I please throughout the study 
 
10. Which one of the following is true regarding medical care for problems resulting from your 
pa
rticipation in this study? 
A. We will provide all necessary medical care for injury or disease resulting from your 
participation in this study as long as you are seen in an Army or DoD, Hospital or Clinic. 
B
. You or your personal insurance will be charged for any medical care rendered for 
problems associated with your participation in this study if you are not seen in an Army or 
DoD
, Hospital or Clinic. 
C. (A) and (B) are both correct. 
 
Score:    Pass:    Not Pass:   
 
   
Signature of Subject   Date  
   
Signature of Reviewer   Date  
 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 71  US Government Proprietary Answer Key: 
Informed Consent Comprehension Assessment: Infectivity Control Subjects 
1) D 
2) A 
3) B 
4) D 
5) A 
6) A 
7) D 
8) C 
9) A
 
10) C 
 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 72  US Government Proprietary APPENDIX C. NHANES I CARDIOVASCULAR RISK CRITERIA 
Figure 1: NHANES I Cardiovascular Risk Criteria for Males 
 
 

Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 73  US Government Proprietary Figure 2: NHANES I Cardiovascular Risk Criteria for Females 
 
 
 

Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 74  US Government Proprietary APPENDIX D. TOXICITY GRADING SCA LE FOR ADVERSE EVENTS 
FOLLOWING MALARIA CHALLENGE 
Grading of Local Solicited Adverse Events Following Challenge 
Local Reaction to 
Challenge  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening 
(Grade  4) 
Pruritus  No interference with 
activity  Repeated use of 
topical steroid > 24 
hours or some 
interference with 
activity  Prevents daily 
activity  Emergency room 
(ER) visit or 
hospitalization  
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 75  US Government Proprietary Grading Scale for Systemic Solicited Adverse Events Following Challenge 
Systemic AE  Mild (Grade 1)  Moderate 
(Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening 
(Grade 4)  
Fever  
(measured orally)  100.4 – 101.1 (°F)  101.2 – 102.0 
(°F) >102.1 (°F)  > 40.0  
> 104.0  
Feverishness  No interference with 
activity  Some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Fatigue  No interference with 
activity  Some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Malaise  No interference with 
activity  Some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Chills  No interference with 
activity  Some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Sweats  No interference with 
activity  Some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Headache  No interference with 
activity  Repeated use of 
non-narcotic pain 
reliever > 24 
hours or some 
interference with 
activity  Significant; any use  of 
narcotic pain reliever or 
prevents daily activity  ER visit or 
hospitalization  
Nausea/Vomiting  No interference with 
activity or 1 -2 
episodes/24 hours  Some 
interference with 
activity or >2 
episodes per 
24 hours  Significant; prevents 
daily activity, and/or 
requires outpatient IV 
hydration.  ER visit or 
hospitalization  for 
hypotensive 
shock  
Diarrhea  2-3 loose stools or 
<400g/24 hours  4-5 stools or 400 -
800g/ 24  hours  6 or more waters stools or 
>800g per 24 hours or 
requires outpatient iv 
hydration  ER vi sit or 
hospitalization  
Myalgias  No interference with 
activity  Repeated use of 
non-narcotic pain 
reliever > 24 hr 
or some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 76  US Government Proprietary Systemic AE  Mild (Grade 1)  Moderate 
(Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening 
(Grade 4)  
Arthralgias  No interference with 
activity  Repeated use of 
non-narcotic pain 
reliever > 24 hr 
or some 
interference with 
activity  Significant; prevents 
daily activity  ER visit or 
hospitalization  
Gastrointestinal 
Symptoms 
(nausea/vomiting/ 
diarrhea/ 
abdominal pain)  No interference with 
activity or 1 –2 
episodes of emesis 
over 24 hr  Some 
interference with 
activity or > 2 
episodes/24 hr, 
requiring oral 
medication  Prevents daily activity, or 
requires outpatient IV 
hydration or IV 
medication  ER visit or 
hospitalization  
Tachycardia – 
beats per minute  101-115 116-130 >130  ER visit or 
hospitalization  for 
arrhythmia  
 
 
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 77  US Government Proprietary Grading Scale for Abnormal Laboratory Values 
Adverse event  Intensity grade  Intensity a 
Hemoglobin (males)  Normal range  12.5 - 17.0 g/dl  
 1 < 13.5 but  12.5 g/dl 
 2 < 12.5 but  10.5 g/dl 
 3 < 10. 5 but > 8.5 g/dl 
 4 < 8.5 g/dl  
Hemoglobin (females)  Normal range  11.5 - 15.0 g/dl  
 1 < 11.5 but  10.5 g/dl  
 2 < 10.5 but  9.5 g/dl  
 3 <9.5 but >8.0 g/dl 
 4 < 8.0 g/dl  
Increase in leukocytes  Normal range  3200 - 10799 cells/mm3 
(WBC)  1 10800 - 15000 cells/mm3 
 2 15001 - 20000 cells/mm3 
 3 20001  - 25000  cells/mm3 
 4 > 25000 cells/mm3 
Decrease in leukocytes  Normal range  3200 - 10800 cells/mm3 
(WBC)  1 2500 - 3199 cells/mm3 
 2 1500 - 2499 cells/mm3 
 3 1000 - 1499 cells/mm3 
  < 1000  cells/mm3 
Decrease in platelets  Normal  140000 - 400000 cells/mm3 
 1 125000 - 139000 cells/mm3 
 2 100000 - 124000 cells/mm3 
 3 25000 - 99999 cells/mm3 
 4 < 25000  cells/mm3 
Alanine 
Aminotransferase  Normal range  Below ULN (60 U/l for males; 40 U/l for females  
 1 1.1 - 2.5 x ULN  
 2 2.6 – 5 x ULN  
 3 > 5 x ULN  
 4 > 10 x ULN  
Infectivity and Diagnostics Equivalence Bridging Study The Surgeon General 
IND 18495; S-18-02 WRAIR #2572 De partment of the Army 
Version 3.0 (13FEB2019) 78  US Government Proprietary Adverse event  Intensity grade  Intensity a 
Aspartate 
Aminotransferase  Normal range  Below ULN (40 U/l for males; 35 U/l for females  
 1 1.1 - 2.5 x ULN  
 2 2.6 – 5 x ULN  
 3 > 5 x ULN  
 4 > 10 x ULN  
Creatinine (males)  Normal range  0.5 - 1.39 mg/dl  
1 1.4 - 1.79 mg/dl  
2 1.8 - 2.0 mg/dl  
 3 2.1-2.5 mg/dl  
 4 > 2.5 mg/dl or requires dialysis  
Creatinine (females)  Normal range  0.5 - 1.29 mg/dl  
 1 1.3 – 1.69 mg/dl  
 2 1.7 – 1.9 mg/dl  
 3 >1.9 mg/dl  
 4 > 2.5 mg/dl or requires dialysis  
Hypoglycemia  Normal range  70-109 mg/dl  
 1 65-69 mg/dl  
 2 55-64 mg/dl  
 3 45-54 mg/dl  
 4 < 45 mg/dl  
Hyperglycemia 
(random)  Normal range  70-109 mg/dl  
 1 110-125 mg/dl  
 2 126-200 mg/dl  
 3 >200 mg/dl  
 4 Insulin requirement or hyperosmolar coma  
ULN: upper limit of normal range  
a Grading scale adapted from “Toxicity grading scale for healthy adult and adolescent volunteers enrolled in 
preventive vaccine clinical trials”, FDA, September 2007. Laboratory values provided in the table serve as 
guidelines.  